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Resumo
A quantidade de medicamentos que se encontra disponível actualmente, a nível comercial, é el-
evada. A importância terapêutica e o proveito destes são indiscutíveis. Contudo, os efeitos de-
sconhecidos de medicamentos individuais e/ou a interacção de efeitos entre medicamentos poderá
acarretar consequências graves para a saúde da população. O seu desenvolvimento e produção
são realizados sob critérios de protecção e segurança, sendo que qualquer medicamento apenas
é aceite para venda, após ter sido sujeito a vários testes pré-clínicos exigentes que confirmem o
seu benefício e traduzam eficácia no tratamento para o qual serão prescritos futuramente. Apesar
de todos os ensaios necessários realizados que antecedem a comercialização de um medicamento,
verifica-se que a sua utilização poderá afectar o corpo do paciente de maneira inesperada por diver-
sos motivos. Deste modo, é essencial manter uma vigilância e monitorização dos medicamentos
numa fase pós-comercialização.
A utilização de alguns medicamentos pode revelar-se insegura e representativa de riscos, uma
vez que a resposta e interacção da população à tomada dos mesmos difere substancialmente.
Verifica-se que, na prática, todas as medidas tomadas na fase pré-comercialização poderão ser
insuficientes, uma vez que factores como a idade do paciente, historial clínico, interacção com
outros medicamentos poderão estar no ápice destes efeitos indesejados.
A Organização Mundial de Saúde (OMS) define Reacção Adversa a Medicamentos (RAM)
como “qualquer efeito prejudicial ou indesejado que se manifeste após a administração do medica-
mento, em doses normalmente utilizadas no homem para profilaxia, diagnóstico ou tratamento de
uma enfermidade”. Apesar deste problema advir de tempos passados, considera-se que a RAM
constitui, actualmente, uma enorme preocupação na saúde pública. Assim, é imprescindível a
partilha de informações, experiências e conhecimento, de modo a que seja possível continuar
a realizar estudos intensivos que visam manter, não só a confiança da população na toma dos
medicamentos, como também a segurança da saúde e bem-estar da mesma.
Os modelos preditivos de Data Mining podem ser uma valiosa ajuda para mitigar o impacto
de RAM desconhecida. A prevenção de erros é uma das principais razões para o uso da tecnologia
na prática farmacêutica. Actualmente, conhecem-se vários métodos informáticos, cujo objectivo
principal é a previsão de efeitos adversos de medicamentos. Assim, os profissionais de saúde po-
dem ser auxiliados pelo desenvolvimento de procedimentos preditivos porque, com essa previsão,
muitos efeitos indesejáveis e desconhecidos sérios, causados pela toma de medicamentos, podem
ser evitados antes destes serem comercializados no mercado.
Este relatório faz um apanhado de estudos existentes de detecção e previsão de efeitos adver-
sos de medicamentos e do contributo possível da informática para a mitigação deste problema.
Em particular, foi feito um estudo teórico e, posteriormente, foram aplicadas as técnicas de Data
Mining para prevenir os efeitos adversos de medicamentos.
i
ii
Abstract
The number of drugs currently available at the commercial level is quite large. The therapeutic
importance and the benefit of these are indisputable. However, unknown effects of individual drugs
and/or the interaction of effects between drugs may have serious consequences for the health of
the population. Although they are developed and produced under safety and security criteria, and
any drug is only accepted for sale after having undergone several demanding pre-clinical tests that
confirms its benefit and translate efficacy into the treatment for which it will be prescribed in the
future. Despite all the necessary tests performed prior to the commercialization of a drug, it is
found that its use can still affect the patient’s body in an unexpected for a number of reasons. It is
therefore essential to maintain the surveillance and monitoring of drugs at a post-marketing stage.
The use of some drugs may prove to be unsafe and risky, since the response and interaction of
the population to their use differ substantially. It is known that in practice and despite all measures
taken during the premarketing phase they may be insufficient, since factors such as the patient’s
age, clinical history and interaction with other medicinal products may be at the apex of these
undesirable effects.
The World Health Organization (WHO) defines Adverse Drug Reaction (ADR) as "any harm-
ful or undesirable effect that manifests itself after administration of the drug at doses normally used
in man for prophylaxis, diagnosis or treatment of a disease." Although this problem has arisen in
the past, it is considered that ADRs are currently a major public health concern. It is therefore es-
sential to share information, experiences and knowledge so that it is possible to continue to carry
out intensive studies aimed at maintaining not only the population’s confidence in the taking of
drugs, but also the health and well-being safety of the same.
A valuable help to mitigate the impact of unknown ADRs can be provided by predictive Data
Mining models. The prevention of errors is one of the main reasons for the use of technology in
pharmaceutical practice. At present, several computer methods are known whose main objective
is the prediction of adverse drug effects. Thus, health professionals can be assisted by the develop-
ment of predictive procedures because, with this prediction, many unwanted and unknown serious
effects caused by drug taking can be avoided before they are marketed.
This report gives an overview of existing studies of detection and prediction of adverse drug
effects and the possible contribution of informatics to the mitigation of this problem. In particular,
a theoretical study was made and, posteriorly, Data Mining techniques were applied to prevent the
adverse effects of drugs.
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Chapter 1
Introduction
This chapter presents a small contextualization of the theme and addresses the main objectives of
this dissertation.
Finally, the structure of the report is presented.
1.1 Contextualization
Currently, Adverse Drug Reactions (ADRs) are a significant public health concern, not only for
patients as well as for the health professionals, as they can potentiate serious injury and even
lead to mortality of individuals. It is considered that these noxious and unintended effects are a
significant reason for the current mortality. About 100,000 deaths are reported annually in the
United States. It is the fourth cause of death. At the same time, the Adverse Drug Events (ADEs)
potentiate the prolongation of hospitalization by about 3-6%, which translates into an increase in
hospital costs that can reach millions of dollars [4, 5, 6].
Thus, continuous monitoring and prediction studies of drugs after marketing is essential, since
the information gathered during the pre-marketing phase may be insufficient and incomplete. The
use of some drugs may prove unsafe and pose risks for the patient due to them characteristics. It
is necessary to consider medication errors such as the dose, duration of treatment or even medical
malpractice, but even when the drugs are used rationally, undesirable effects may occur during
treatment [7, 8, 9].
It is recognized that ADRs are a major global concern and therefore have been the subject of
ongoing studies and research aimed primarily at increasing patient safety and protection. Com-
puter technology has been playing a crucial and extremely important role in the health care. It
is considered that the growth of health knowledge is directly proportional to the increase in the
development of information technology. Prevention of errors is a primary reason for use of tech-
nology in pharmaceutical practice. Recently there has been a lot of research in developing to
predict ADRs. The development of predictive procedures would help health professionals, since
they could avoid many unwanted and unknown serious effects before marketing the drug. In par-
allel, these methods could also reduce hospital costs. Preserving the quality, safety and efficacy
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of all drugs and ensuring the well-being of the population is the determining factor in this matter
[10, 11, 12].
1.2 Objectives
The main goal of this dissertation is to assess how useful Data Mining methods and algorithms
can predict the adverse effect of drugs. Thus, several key points have to be studied and addressed.
In the first stage, the main objectives are not only study and understand the basic concepts
inherent to the adverse effects of drugs, but also analyze sites and databases where data and infor-
mation concerning ADRs is available. After this research, it is important to investigate studies and
methods that already exist to predict these effects and, finally, explore the tools of Data Mining
and assimilate the interest of this method in predicting adverse effects of drugs.
The idea is to choose drugs, whose effects are known and available in a reliable database, and
use a Data Mining tool to predict such known effects. That is, in order to verify if the tool used is
feasible to predict unknown adverse effects of drugs, is performed a simulation where if supposes
that adverse effects of selected drugs are not known and, through the crossing of data of other
drugs, it is intended discover the adverse effects of drugs.
Thus, it is extremely important to put two research questions:
H1) can data mining software be useful for the process of prediction and explanation of adverse
drug effects?
H2) does the use of additional information from the Chemistry domain improves the perfor-
mance of data mining algorithms?
The answer to these questions is debated in the Chapter 5, in section 5.1.
1.3 Structure of the Report
This report has five chapters. The current chapter has presented the context of the dissertation,
its motivation and its objectives. Chapter 2 introduces the state-of-art of adverse effects of drugs
and Data Mining concepts. Various tasks and tools available in Data Mining are also described
in Chapter 2. This chapter also surveys relevant ontologies and standards. Chapter 3 focuses
primarily on project implementation. It presents not only a description of the data used and its
pre-processing, but also details the processes performed and the algorithms used. The results
obtained and some conclusions of these are addressed in Chapter 4. Finally, Chapter 5 describes
the most relevant conclusions and suggests future work.
Chapter 2
Survey on Adverse Drug Reactions and
Data Mining
This chapter surveys the essential topics of the domain of this study. It approaches the basic con-
cepts related to drugs and adverse drug reactions and their underlying factors. The risks involving
the use of drugs are reported together with the importance of monitoring of drugs in the post-
marketing phase. Finally, it is presented a description of Data Mining state-of-art methods and
algorithms and of the tools that currently can be used to predict adverse drug reactions.
2.1 Adverse Drug Reactions
As is general knowledge, the use of drugs 1 is very common, most often, prescribed by compe-
tent authorities as doctors or health professionals, in order to treat diseases or improve a health
problem. Although drugs are considered generally effective in the treatment for the disease they
were prescribed, the impact of their use in society has several perspectives. Drugs can affect the
body of those who use them in unexpected and harmful ways for a variety of reasons, which may
influence their medicinal and therapeutic efficacy 2, 3, [7, 13, 14].
All commercially available and marketable drugs have previously been subject to a number
of pre-clinical tests, in order to prove their efficacy and safety. Thus, any drug is only approved
for sale in the market if it is found that it has more benefits than risks for patients. However,
because knows itself that no drug is risk free, surveillance of drugs after marketing is essential and
extremely necessary [9, 14, 15].
1A medicinal product is any substance or combination of substances presented as possessing curative or preventive
properties for diseases in humans or their symptoms or that may be used or administered to humans in order to establish
a medical diagnosis or, by exerting a pharmacological action, immune or metabolic, to restore, correct or modify
physiological functions.
2"Interações medicamentosas." Available in http://www.ebah.pt/content/ABAAAAjBUAE/interacoes-
medicamentosas, accessed last time in 22-10-2016
3"Medicamento." Available in http://www.apifarma.pt/apifarma/areas/saudehumana/Paginas/default.aspx, accessed
last time in 23-10-2016
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The World Health Organization (WHO) defines Adverse Drug Reaction (ADR) as "any harm-
ful or undesired effect which manifests itself after drug administration at doses normally used in
man for the prophylaxis, diagnosis or treatment of a disease" [7, 8, 9].
There are certain factors that may be at the origin of possible occurrences of ADRs. This
concludes that there is a higher incidence of ADRs in certain situations. It is then observed that
the age and gender of the patient, the number of drugs administered and the interaction that occurs
between them, the pathological condition, the existence of allergies and genetic factors could
promote the occurrence of an ADR [14].
Adverse Drug Reactions classification
A lot of research has been done recently on ADRs. It is currently possible to classify them accord-
ing to their severity and causality. In 1999, Wills and Brown [15] proposed an organization for to
classify the ADRs, dividing them into nine main categories:
Reaction type A - usually depend on the dose, can be predictable, have low mortality and occur
more often. Eg., poisoning digoxins in patients with kidney disease;
Reaction type B - for the most part are pharmacologically predictable, involves the interaction
with the host microorganism and disappear with the removal of the causative agent. That
differs from type A by the fact that it occur in the organism physiology. Eg., superinfections
with the use of broad-spectrum antibiotics;
Reaction type C - concerns the concentration of the pathogenic agent and chemical character-
istics and not the pharmacological effect of the drug. Eg., gastrointestinal injury by local
irritant;
Reaction type D - depends on the physical nature of the preparation (formulation). The reaction
ends when the drug is withdrawed or replaced. Eg., inflammation around implants;
Reaction type E - derived of the withdrawal or reduction in dose of drug and is pharmacologi-
cally predictable. Eg., tricyclic antidepressants;
Reaction type F - appears only in susceptible individuals, genetically determined. Eg., hemolysis
with the use of sulfonamides for disabled glucose 6-phosphate dehydrogenase;
Reaction type G - genotoxic effects of medicines cause irreversible genetic damage. Eg., thalido-
mide;
Reaction type H - pharmacologically unpredictable, it is not dose-related, arises from the acti-
vation of the immune system and only disappears with drug withdrawal. Eg., anaphylactic
shock caused by penicillin;
Reaction type U - despite not knowing the mechanisms of action, it is known that does not fit the
above categories. Eg., vomiting after anesthesia.
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Relatively to severity, ADRs are categorized into: [7, 9, 16].
Light - does not involve the withdrawal of the drug or require additional treatment;
Moderate - does not involve removal of the drug, but is necessary a modification of treatment;
Serious - involves drug withdrawal and cessation of treatment, and can be fatal or result in per-
sistent or significant disability and requires hospital care;
Lethal - fatal to the patient.
Similarly, Karch and Lasagna in 1975 4 proposed the following ADRs classification according
to causality: [7, 9, 13].
Defined - meets a chronological sequence and follows a known response;
Probable - meets a chronological sequence and follows a known response, however cannot be
explained by the known characteristics of the patient’s clinical status;
Possible - meets a chronological sequence and follow a known response, however it may have
been a result of the clinical state of the patient or other treatments that are being performed
simultaneously;
Conditional - meets a chronological sequence, but does not follow a known response and cannot
be explained by the known characteristics;
Doubtful - any reaction that does not follow the rules described above.
Patient-related factors that predispose to Adverse Drug Reactions
There is great disparity in the way people respond and interact with the drugs. Thus, although all
tests and clinical tests performed in order to ensure not only in produce satisfactory results such
as the improvement in the quality of life of the population, they have some limitations that must
be taken into consideration. Some tests in animals are insufficient to provide safety to human
patients. The number of patients involved in these studies is very limited. The short duration of
tests and the amounts of the doses, which may not correspond to the time/dosage actual required
to treatment. The exclusion of individuals who have diseases or are old/children. All of these are
considered the main conditions limiting these clinical trials 5, 6, [4, 14, 17].
It is extremely important to note that there are certain groups of individuals more susceptible
to the occurrence of ADRs, such as the elderly/children/women or individuals who have a clinical
4"Trabalho de Farmacologia sobre reações adversas", Marcelo Santos. Available in
http://www.ebah.pt/content/ABAAABIYwAB/trabalho-farmacologia-sobre-reacoes-adversas?part=2, accessed last
time in 16-01-2017
5"Farmacovigilância: Reações adversas a medicamentos", August 2008. Available in
http://www.ufrgs.br/boletimcimrs, accessed last time in 22-10-2016
6What are adverse drug reactions? Available in http://www.adr-database.com/What%20are%20ADRs.html, ac-
cessed last time in 23-10-2016
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history of diseases. It is also verified that there is a direct relation between the number of drugs
that a patient takes, that is, the probability of an ADR occurring increases with the number of
drugs ingested by the patient. The administration of large doses of drugs promotes the occurrence
of ADRs. It is also important to note that individuals with allergies or those with liver, heart or
kidney disease are more easily affected. For this reason, this type of population will have to have
adequate and continuous clinical monitoring [14, 16, 18].
Drug-Drug Interaction
Several previous studies claim that a very relevant factor that can increase the number of ADRs
episodes is the simultaneous consumption of more than one drug, since drugs are chemical com-
pounds that can interact with each other, triggering, in this way unwanted responses and some-
times having toxic effects. Thus, it is essential to study not only the occurrence of ADR episodes
in isolation, but also the possible drug interactions that may exist and the relationships that can be
created between the two [16, 18].
Currently, it is found that the majority of the medicated population consumes more than one
drug. On the one hand, we have situations in which the taking of these is independent, that is, they
are used for different purposes of treatment (for example, one drug serves to lower cholesterol
and another drug serves to raise blood pressure) and, on the other hand, the taking of these may
be dependent, that is, when they are used together for the same treatment. The simultaneous
taking of several drugs is one of the most worrying and relevant issues in clinical practice, and
health professionals should be fully aware of the patients’ medical history: drugs taken, doses
administered, period of time taken, diseases, etc., in order to guarantee their safety.
As is well known, the prescription of drugs is totally performed with the purpose of guarantee-
ing benefit to the patient, contributing to their well-being and significantly improving their health
and quality of life, thus, the simultaneous use of medication is a therapeutic strategy widely used
and, most of the times, necessary, which enhances the effectiveness of the drugs and, consequently,
the beneficial effects of the treatment. At the same time, however, their interaction may not only
lead to unwanted responses, but may also change the intended effects, since they are chemical
substances that may be interacting with each other, with the receptors or with agents around them.
The chemical responsible for the therapeutic action is called the active principle of the drug. The
activity of the drug can be determined by its chemical structure. Thus, after it comes into con-
tact with the body or after it interacts with another drug, a change in the molecular structure of
the drug’s active principle may occur, and thus, the occurrence of ADRs will be induced 2, 7, 8,
[18, 19].
Briefly, the Drug-Drug Interaction (DDI) comes from the simultaneous ingestion of two or
more drugs and consists in the alteration of the effects of the individual drugs, which may result
either in the increase or decrease in toxicity or most often in the increase/reduction in terms of
7"Farmacologia molecular." Available in http://antonini.med.br/geral/farmol.html, accessed last time in 17-11-2016
8"Divisões e conceitos da farmacologia", July2015. Available inhttp://luizcarlosfarmaceutico.webnode.com/news/divisoes-
de-conceitos-de-farmacologia/, accessed last time in 17-11-2016
2.1 Adverse Drug Reactions 7
therapeutic efficacy, DDIs are dangerous and endanger the lives of patients. Several studies have
demonstrated the direct relationship between the number of drugs consumed and the incidence
of ADRs. It is observed that the probability of a patient having an increases with the number of
drugs taken (ranging from 3-5% for patients who take 2 to 3 drugs, increasing to 20% or more,
in patients consuming 10 to 20 drugs). A recent study in a set of hospitals in the USA revealed
that about 22% of the ADRs are due to DDIs. This value reveals the extreme importance and
necessity of methods and tools that help and guide health professionals so that they can make
credible decisions with a lower risk of toxicity to patients. It is also notorious that the incidence
of DDI is more susceptible both in the elderly and in the patients who are hospitalized, since
they have a weakened organism, as well as in children, since they may not yet have the organism
fully prepared. In this way, the role of health professionals is extremely important and has a great
responsibility to combat this problem, since taking into account the factors mentioned above and
with knowledge of the characteristics of the drugs, many DDIs could be avoided [20, 21, 22].
Regarding the nature, DDI may be pharmaceutical, pharmacokinetic or pharmacodynamic.
For D.G. Grahame-Smith and J. K. Aronson [7], the pharmaceutical DDI, also called drug in-
compatibility, comprises "physical-chemical events that result in the loss of activity of one or both
of the drugs." These occur before the administration of the drugs, that is, outside the body, when
the drugs are placed and mixed in the same container. Usually, this type of DDI can be observed
in the preparation of drugs, since they usually result in color/consistency or precipitation changes
and may cause the formation of a new compound or decrease/inactivate the desired activity of the
drugs. It is known that the drugs most susceptible to this type of DDI are those that require con-
tinuous infusion (Example: Penicillin is capable of inactivating the aminoglycosides when they
are mixed). On the other hand, it is reported that pharmacokinetic-type DDIs are the most fre-
quent ones, and are unfortunately the most difficult to predict, since they appear in drugs with
unrelated active principles. This type of DDI comprises significant changes in parameters such as
plasma concentrations and affects mechanisms such as absorption, distribution, metabolization or
excretion of the drug. Absorption of the medicinal products may be impaired as they may become
insoluble in the body due to, for example, gastrointestinal pH changes that may occur when the
drugs interact. Several studies mention that the antacids drug group has the ability to decrease the
absorption of other drugs. The distribution process is characterized by the arrangement of the drug
in the tissues, and for this, many drugs bind to plasma proteins. Thus, it is easy to see that when
there is simultaneous taking of more than one drug, there may be competition for these plasma pro-
teins, and the connection with them will occur with the drug that has the most affinity to it, thus
avoiding the correct distribution of drugs. This happens when warfarin and coral hydrate are in-
gested in parallel. In this case, coral hydrate is responsible for non-binding of warfarin to plasma
proteins, thereby increasing the plasma concentration of warfarin. During the metabolism the
transformation of drugs, through biochemical reactions catalyzed by enzymes essentially hepatic
occurs. Presently, some drugs are known that can both induce or inhibit enzyme activity, which
may cause the loss/reduction of the action of the drug to be ingested in concomitance. Fentoin,
defined as an enzyme inducer, when interacting with oral contraceptives cuts the effect of them.
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Excretion, that is, elimination of drugs happens essentially in the kidneys. The rate of this can be
altered, that is, it may take more or less time than expected, by the interaction of drugs, causing
the increase or decrease of concentration of the drug in the body, respectively. It is known that the
time of action of the antibiotic penicillin is amplified when it is taken together with the probenecid
drug, since the second has the ability to inhibit the secretion of the former, which can produce a
toxic effect. Finally, it is also important to approach the DDI of the pharmacodynamic category,
since it is responsible for interfering in both the biochemical and physiological effects of the drug,
thus occurring at the site of its action, at the level of the pharmacological receptors. Depending
on the type of effect it produces, the response of this type of DDI can be of two types. If the
product is potentialization of the effect, that is, if the effect of the drug is similar to that predicted,
but increased, synergism occurs. This happens when the drug acts at different pharmacological
receptors. If, on the other hand, the result is a worsening of side effects, that is, if the effect of the
drug is the opposite of what is intended, there is antagonism. This occurs when drugs compete for
the same pharmacological receptors, being that one of which antagonizes or suppresses the other.
Potentialization of the effect arises when the combined effect of two or more drugs is greater than
the isolated effects of each drug. Usually, these effects are predictable and can be used to bene-
fit and maximize therapeutic action, however, they can also cause toxicity. An example of DDI
of this type is the association of medications such as aminoglycoside and vancomycin, in which
the production of toxic effects to the patient occurs. Analogously, the combination of diuretics
harms the effects of the drug digoxin and is therefore an example of an IDD of an antagonistic
pharmacodynamic nature 9, 10, [18, 20, 21].
From another perspective, DDIs can be classified as mild, moderate or severe. They are called
mild, when it is not necessary to change or withdraw the drugs in question. For example: the effect
of the diuretic furosemide is decreased by the analgesic acetaminophen, however their combination
does not result in toxic effects for the patient. When the patient’s clinical condition worsens, DDI
is said to be moderate. For example: Simultaneous use of the antibiotic rifampicin and the anti-
tuberculosis drug called isoniazid. In case of irreversible/permanent effects and possibility of death
of the patient, the DDI is designated as severe. For example: The combination of the antihistamine
terfenadine and the antifungal ketoconazole potentiates the occurrence of cardiac arrhythmias.
There is some relevant information about drugs that should be taken into consideration at the time
of prescription, in order to avoid certain DDIs. Thus, drugs such as aspirin, warfarin and enzyme
inhibitors are known to have the potential to interact with other drugs and potentiate toxic effects 2,
[7].
In conclusion: despite all the analyzes performed, the existing information about drugs, the
previously reported factors that are likely to induce the occurrence of an DDI and the enormous
knowledge of health professionals, it is still difficult to predict with absolute certainty a DDI.
9"Interação entre medicamentos: mantenha-se alerta." Available in https://advancecare.pt/interacao-entre-
medicamentos-mantenha-se-alerta/,accessed last time in 23-10-2016
10"Principais interações medicamentosas e drogas associadas com efeito", 2008. Available in
http://boaspraticasfarmaceuticas.blogspot.pt/2008/10/principais-interaes-meicamentosas-e.html,accessed last time
in 23-10-2016
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This occur because each patient is different and can react differently to drugs. For this reason,
the role of health professionals is very important, as they should analyze each case in depth and
pay special attention to the symptoms that arise from DDIs. It is certainly essential to have other
options. Thus, it is necessary to select substitute drugs and, if this is not possible, it is essential
to adjust doses, implement alternative therapeutic strategies and regularly monitor the patient, in
order to try to ensure maximum patient safety and treatment efficacy. The health professionals
should also notify the competent authorities of the occurrence of an ADR in order to alert, protect
and avoid other similar occurrences 2, 9, 11, 12, [21].
Post-marketing Safety monitoring of drugs
Continuous surveillance of medicinal products after they have been marketed is extremely neces-
sary and essential, since not only there are the numerous factors mentioned previously (mentioned
in 2.1) which make the tests carried out at the pre-marketing stage incomplete and imperfect, es-
pecially with regard to possible adverse reactions, as well as changes in the risk/benefit ratio may
occur over time as new information and occurrences on the use of such a medicinal product arise.
Studies have estimated that in about half of the drugs new adverse reactions are only known after
being approved for sale. Thus, after the drugs are available on the market, care should be taken to
identify any new risks as quickly as possible and thus to ensure maximum safety and protection in
order to avoid harmful harm to patients 5,13, [4, 12, 23].
The awareness about the need to implement drug surveillance systems whose sale was already
allowed came only in the 1960s when the tragic accident with the drug thalidomide prescribed
for pregnant women, responsible for the birth of infants with congenital malformations, occurred.
This event forced the withdrawal of the drug and since then several cases have been known whose
drugs were withdrawn from the market because they put the patients’ life in danger. It is important
to note that, despite the enormous concern regarding global health that this implies, pharmaceutical
companies are also affected by billions of euros [4, 11, 24]. Since then, several countries began to
use PharmacoVigilance (PhV) systems, that is, drug safety monitoring systems, to identify and
detect ADRs, improve public health and avoid financial risks. PharmacoVigilance is defined by
WHO [25] as "the science and activities relating to the detection, assessment, understanding and
prevention of adverse effects or any other drug-related problem" 21, [10, 26, 27]. The aim of this
system is to recognize unknown DDIs, to detect ADRs early on, to improve the rational use of
drugs and, consequently, to reduce the mortality rates that come from ADRs [10, 12, 15].
Currently, the most used tool and that constitutes the primordial source in PhV is denominated
spontaneous notification. This is the communication of suspected ADRs, signs or symptoms de-
tected by both health professionals and patients, in order to inform and alert the regulatory and
responsible entities of the drugs so that they analyze the data provided and verify the veracity of
11Clinically important, common drug-drug interactions (ddis). Available in https://crediblemeds.org/healthcare-
providers/drug-drug-interaction, accessed last time in 22-10-2016
12"Novidades sobre a indústria farmacêutica no brasil." Available in http://www.hipolabor.com.br/blog/2015/05/04/hi
polabor-explica-voce-sabe-o-que-e-interacao-medicamentosa/,accessed last time in 22-10-2016
13Pharmacovigilance, 2015. Available in http://www.ufrgs.br/boletimcimrs, accessed last time in 22-10-2016
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the information, in order to continue to ensure the quality, efficacy and safety of the medicinal
product and, if necessary, to suspend or withdraw it from the market. These participations are
conducted in Spontaneous Reporting Systems (SRS) at national level and are stored in databases
and sent to the WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring
Centre - UMC), so that information is shared between the countries and other European Medicines
Agency (EMA) 14, [23, 25, 28]. Although this method contributes essentially to the continuous
protection of the overall health and improvement of therapeutic practice and is very relevant in
post-marketing surveillance, it presents a great disadvantage and limitation, since it does not allow
a direct benefit to the patient, that is, this system is only applicable after the patients have been
targeted by the ADRs [15, 24, 29].
Analogously, a number of studies and research have emerged whose main purpose is the de-
velopment of systems and the use of computational methods, such as Data Mining techniques.
Predictive methods may predict possible ADRs before they actually occur, significantly improv-
ing public health and safety in drug taking [4, 24, 26].
Web Data Repositories
With this "collective" participation is possible to alert the competent entities about occurrences of
ADR. To collect information about ADRs and to compare experiences it requires the participation
and collaboration of health professionals, regulators and users [10, 11, 12].
By 1968, WHO formed the Programme for International Drug Monitoring (PIDM) to
gather information on ADRs at the international level. The main objective of this program is to
facilitate the communication between countries to facilitate the identification of ADRs through
reports and case reports. WHO coordinates the system for quantification and detection of adverse
reactions by the Collaborating Center of Uppsala Monitoring Center, whose main function is to
organize the participation of all 120 countries that maintain VigiBase 15, a worldwide database on
ADRs. Typically, these countries provide similar reporting forms in order to establish a standard
with a certain level of consistency in the information collected. This database provide public ac-
cess to nearly 10 million ADRs. To do this, it is only necessary to enter the name of the drug at the
research site. This research makes it possible to see the types of reactions that were reported for the
product, broken down by category and frequency, geographic distribution, age group, patient gen-
der and number of ADRs per year. The data contained in VigiAcess (http://www.vigiaccess.org/)
are aggregated so that both the entity of the notifying person and the country where the notification
was made be kept confidential 16, 17, [12, 14].
14Report side effects. Available in http://www.medicinesauthority.gov.mt/adversedrugreactions?l=1, accessed last
time in 26-10-2016
15VigiBase. Available in http://www.umc-products.com/DynPage.aspx?id=73590mn1=1107mn2=1132, accessed
last time in 19-01-2017
16Who makes drug side effects easier to find with new database, April. Available in http://www.raps.org/Regulatory-
Focus/News/2015/04/23/22034/WHO-Makes-Drug-Side-Effects-Easier-to-Find-With-New-Database/, accessed last
time in 26-10-2016
17VigiAccess. Available in http://www.vigiaccess.org/, accessed last time in 18-11-2016
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There are several databases available on the Internet for ADR reporting. Most are free and
with public access to the reports provided and to both the data and the conditions under which
these ADRs were experienced.
All reports concerning ADRs within the European Union (EU) as well as reports from outside
the EU submitted by the marketing authorization holders in accordance with EU law are main-
tained by the EMA in a database called EudraVigilance 18. In order to ensure the anonymity
of data subjects and the protection of data, these are not available in full to the general public.
Aggregate data can be seen by age group, gender, type of suspected side effect and outcome 19,
[25].
DrugBank is a freely available database storing a large amount of molecules information. It is
considered a unique biology and chemistry resource that contains detailed data not only of drugs,
but also of the amino acid sequence, structure and route of administration. It has approximately
8261 drug entries. It allows one to search by medication, category, reaction, pathway, gene, tar-
get protein, class or indication and collects/reviews information in more than 50 databases/web
applications. Data are available in XML format 20. For our study it is important that DrugBank
has information concerning drug-drug interaction. It is also valuable for classification tasks as we
have in the study the hierarchical taxonomy of the molecules.
There is also a database called ADverse Reaction Classification System (ADReCS) which
provides the standardization and hierarchical classification in four levels of ADR terms. The
information contained in this database originates from medical repositories such as DailyMed
(http://dailymed.nlm.nih.gov/dailymed/about.cfm), MedDRA (http://www.meddra.org/), DrugBank
(http://www.drugbank.ca/) or PubChem (https://pubchem.ncbi.nlm.nih.gov/). It contain informa-
tion on 1698 drugs and 6972 ADR terms, in a total of 157246 drug-adverse events. Academic
users can access this data free of charge at http://bioinf.xmu.edu.cn/ADReCS/download.jsp. Data
are available in XML format 21, [5].
OpenFDA was designed in 2014 with the main objective of allow public upload of ADR cases.
Is an excellent and complete data source. It contains and provide numerous personal data, such as
the list of drugs administered by them and their associated ADRs. Offers the possibility for users
to download structured data, namely adverse events and drug labels. These informations are very
important and useful since it can allow and facilitate the study of possible DDIs 22.
The well-known regulatory agency of drugs, US Food and Drug Administration (FDA), is re-
sponsible for, among other things, ensuring the safety and efficacy of drugs in order to preserve the
health of the population. With this objective in mind, FDA has developed the FDA Adverse Event
18European database of suspected adverse drug reaction reports. Available in
http://www.adrreports.eu/en/eudravigilance.html, accessed last time in 19-01-2017
19Medicines authority. Available in http://medicinesauthority.gov.mt/missionobjectives?l=1, accessed last time in
19-11-2016
20DrugBank. Available in https://www.drugbank.ca/about, accessed last time in 09-06-2017
21Xiamen University. Adrecs, 2014. Available in http://bioinf.xmu.edu.cn/ADReCS/, accessed last time in 19-11-
2016
22About openFDA. Available in https://open.fda.gov/about/, accessed last time in 18-01-2017
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Reporting System (FAERS) 23 that contains adverse reactions and medication error reports. It
has a program called MedWatch, enabling the report of possible ADRs. At the moment (2016), it
has already nearly 2 million reports. It is important to note that since these are spontaneous reports
made by people, mostly without any medical knowledge, the data contained in the reports is not
completely reliable 24, [4].
SIDe Effect Resource (SIDER) 25, hosted by the European Molecular Biology Laboratory,
provides access to information on marketed drugs and stores around 5880 data on ADRs. The
information contained in this database is standardized using the Medical Dictionary for Regula-
tory Activities (MedDRA) and comes from both public and bulletin documents. This data can be
downloaded in text format. In addition to allow users to search for drugs and ADRs, SIDER fea-
tures a GitHub repository where they can report error detection in the information made available
[11, 30].
The partnership of two companies - INPS (IN Practice Systems) and EPIC - gave rise in 2003
to the database of the The Health Improvement Network (THIN) 26 in the United Kingdom.
This database covers the electronic medical records of 11.1 million patients from hospital practice
that were processed, validated and kept anonymous by CSD Medical Research UK. THIN contains
two types of data called "therapy" and data defined as "doctors". The first relates essentially to
the details of patient prescriptions. The second stores both symptoms, diagnoses and medical
interventions. The diagnoses provided are coded using hierarchical codes, in order to follow a
pattern [27].
There are also several online forums such as PatientsLikeMe 27 or blogs where it is possible
to share patient self-reports about one’s experiences with the use of medication. The reliability
of the information provided is questionable, but this sharing of information is always relevant and
necessary, since it can provide useful information on some drugs [10, 26].
In order to understand how adverse reactions occur, it is necessary to perceive the mechanisms
they take on drugs at the molecular level. Both access to chemical and biological information
may aid in understanding the molecular mechanisms involved and can be found at the source of
adverse reactions. There are currently some servers that collect this information. The IntSide
web server is updated each 6 months and contains about 1175 side-effects of 996 drugs. These
are divided, based on an analysis performed by Miquel Duran-Frigola and Patrick Aloy [31],
into eight categories according to biology and chemistry: Targets, Proteins, Pathways, Processes,
Functions, Fragments, Scaffolds and Structural Terms. Users can scan up to three Side Effects
(SEs) at a time and the server will produce different networks displaying the common biological
23FDA Adverse Event Reporting System. Available in https://open.fda.gov/data/faers/, accessed last time in 19-01-
2017
24U.S FOOD DRUG ADMINISTRATION. Available in http://www.fda.gov/default.htm, accessed last time in 18-
11-2016
25SIDER 4.1: Side Effect Resource. Available in http://sideeffects.embl.de/, accessed last time in 19-11-2016
26The health improvement network (thin) research team, April 2015. Available in
https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database, accessed last time in 19-11-2016
27Available in https://www.patientslikeme.com/, accessed last time in 19-11-2016
2.1 Adverse Drug Reactions 13
and chemical characteristics associated with each SE. These networks have the identification of
complex mechanisms 28.
Comparative Toxicogenomics Database (CTD) was developed at the North Carolina State
University (NCSU) and is publicly available for free via TOXNET 29, supported by funds from
the National Institute of Environmental Health Sciences (NIEHS). This database gathers manu-
ally curved information on the interactions that occur between molecular mechanisms: chemical-
gene/protein interactions, chemical-disease interactions and gene-disease interactions. The main
objective is to provide an insight into how chemicals relate to and influence human health, help-
ing to develop relationships that may be at the root of side effects. The gene for cross-linked
CTDs (symbols, names and data) is derived from the Gene Database of the National Center for
Biotechnology Information (NCBI), a division of the US National Library of Medicine 30, 31, [32].
Molecular Descriptors and Tools
Several studies have shown that the Structure-Activity Relationship (SAR) of substances can be
investigated using molecular descriptors. For R. Todeschini and V. Consonni 32, “the molecular
descriptor is the final result of a logic and mathematical procedure which transforms chemical
information encoded within a symbolic representation of a molecule into a useful number or the
result of some standardized experiment”. Normally these are used for the purpose of predicting
the properties of substances, manipulating and analyzing chemical structural information in order
to classify chemical structures and seek a similarity between them 33,34, 35, [33].
According to Katritzk and Gordeeva [34], molecular descriptors are divided into: topologi-
cal, electronic, geometric or combined. The so-called topological descriptors are obtained by
the two-dimensional (2D) graphical representation of molecules and characterize both size and
molecular form. In turn, those that are calculated through quantum chemistry are known as elec-
tronic descriptors. They allow the expression of both the electronic properties of the molecules,
as well as their interactions. M. Karelson and V. S. Lobanov [35], in 1996, verified the importance
and usefulness of this type of descriptors in the development of Quantitative Structure-Activity
Relationships (QSAR)/Quantitative Structure-Property Relationships (QSPR) with the chemical,
physical, biochemical and pharmacological properties of the compounds. The differentiation of
molecules by their topology is a function of the geometric descriptors. The use of this type of
28Intside, 2015. Available in http://intside.irbbarcelona.org/index.php, accessed last time in 24-11-2016
29Available in http://toxnet.nlm.nih.gov, accessed last time in 24-11-2016
30Comparative Toxicogenomics Database. Available in http://ctdbase.org/, accessed last time in 24-11-2016
31Fact Sheet Comparative Toxicogenomics Database (CTD), 2014. Available in
https://www.nlm.nih.gov/pubs/factsheets/ctdfs.html, accessed last time in 24-11-2016
32What is a molecular descriptor, 2000. Available in http://www.moleculardescriptors.eu/tutorials/T1_moleculardescr
iptors_what_is.pdf, accessed last time in 24-11-2016
33An integrated web-based platform for molecular descriptor and fingerprint computation, March 2015. Available in
http://www.scbdd.com/chemdes/, accessed last time in 17-11-2016
34Molecular descriptors: An introduction, 2006. Available in http://infochim.u-
strasbg.fr/CS3/program/material/Todeschini.pdf, accessed last time in 24-11-2016
35"Descritores moleculares para aprendizagem automática (“Machine learning”)." Available in
http://joao.airesdesousa.com/agregacao/slides_2013/descritores_QSPR_slides.pdf, accessed last time in 24-11-2016
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descriptors requires knowledge of the three-dimensional (3D) coordinates of the atoms of the
molecule. Finally, the descriptors are called combined when they are calculated by computer-
assisted methods. This category of descriptors is responsible for grouping information about the
topological environment of each atom and about the electronic interactions due to the presence of
other atoms in the molecule 34, 35, 36, [36].
The interconversion of molecular structures between representations constitutes a huge prob-
lem in computational modeling. Thus, tools are needed to facilitate the extraction and interpreta-
tion of chemical data [37].
Open Babel is an open source tool freely available from the Open Babel website and ad-
dresses the languages of chemical data. It is used for a wide variety of purposes, among which
are the filtering, conversion, analysis and storage of molecular modeling data. Thus, this tool is a
good option for the proliferation of multiple formats of chemical files, since it has the capacity to
interconvert more than 110 chemical file formats 37, [37].
Fingerprints: The Open Babel tool has the ability to identify all the linear and ring substructures
of a molecule. These are mapped to a bit sequence, known as the fingerprint of the molecule,
of length 1024 using a hash function. In addition to having the ability to reduce the search
time of a molecule, fingerprints also facilitate the identification of similar molecules.
SMILES - Represents the language used to identify a molecule. Such language complies with a
set of rules. This allows the identification of a molecule by one and only one SMILES. This
translates into an advantage in eliminating duplicates.
2D and 3D coordinates - Open Babel produces the 2D and 3D coordinates of a molecule through
its SMILES identifier.
In Figure 2.1, it can be seen a representation of the three different ways of identifying the
same molecule: SMILES identifier - considered a 0D structure (above); 2D (left side) and 3D
(right side). These three structures can be identified and converted to one another using Open
Babel.
Like as Open Babel, PaDEL is an open source tool used to calculate molecular descriptors
and fingerprints. Molecular fingerprints designate the property of a molecule. Usually, they are
presented in the form of bits or as vector representations to indicate, respectively, the existence
of certain properties and the frequency of these. Currently, this software calculates approximately
1875 - molecular descriptors: 1444 are 1D and 2D descriptors and 431 are 3D descriptors - and
about 12 types of fingerprints 38, 39, [38].
36What is a molecular descriptor, 2000. Available in http://www.moleculardescriptors.eu/tutorials/T1_moleculardescr
iptors_what_is.pdf, accessed last time in 24-11-2016
37Open babel: The open source chemistry toolbox, 2011. Available in http://openbabel.org/wiki/Main_Page, ac-
cessed last time in 17-11-2016
38PaDEL-Descriptor, July 2014. Available in http://www.yapcwsoft.com/dd/padeldescriptor/, accessed last time in
17-11-2016
39Chemical descriptors calculation. Available in http://crdd.osdd.net/descriptors.php, accessed last time in 17-11-
2016
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Figure 2.1: Identifiers of the molecule Sertraline
2.2 Data Mining
The amount of existing information and data stored in databases or files, in several areas, is quite
large. To be able to take advantage of such data, powerful tools are required. Being able to analyze,
interpret data and extract the most potentially useful knowledge from them, would enable use to
make more conscious and relevant decisions [39, 40, 41].
Knowledge Discovery in Databases (KDD) is a technological answer to this need. Fayyad
et al. [42, 43] describe KDD as being "a non-trivial process of identifying new valid, useful and
understandable patterns". Thus, as the name implies, KDD aims at finding useful knowledge by
extracting information from a database. It presents steps such as data selection, data cleansing, data
transformation, being that according to Fayyad et al. [42, 43], "Data Mining (DM) is considered
the main phase of this whole process and consists in the accomplishment of data analysis and the
application of discovery algorithms that, under certain computational limitations, produce a set of
patterns of certain data" [43, 44, 45]. In Figure 2.2, it can be seen a representation of the KDD
process 40.
Figure 2.2: KDD Process.
DM is currently one of the most effective techniques for extracting knowledge from large
40Knowledge Discovery in Databases (KDD). Available in http://www.infovis-
wiki.net/index.php?title=Knowledge_Discovery_in_Databases_(KDD), accessed last time in 17-11-2016
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volumes of data. This exploration tool involves statistical methods, artificial intelligence tech-
niques, namely machine learning, and specific algorithms and allows data segmentation, pat-
tern/model discovery and significant correlations, and the extraction of structures [46, 47, 48].
Defined by Cabena et al. [43] as "a multidisciplinary field that combines knowledge machine
techniques, pattern recognition, statistics, database and visualization, to extract information from
large databases", DM has shown to be very promising in several areas, having satisfactory applica-
bility in marketing, medicine, commerce, telecommunications, astronomy, fraud detection, among
others [44, 49, 50].
In order to better answer the question in cause and to efficiently extract knowledge from the
databases, different algorithms and tasks are applied, depending on the type of problem to be
solved [39, 44, 49].
CRISP-DM
DM is characterized by several processes. Currently, the CRISP-DM (CRoss-Industry Standard
Process for Data Mining) [51] is considered the most accepted standard. As can be seen in Fig-
ure 2.3, the CRISP-DM process is a six-stage cycle: Business Understanding, Data Understanding,
Data Preparation, Modeling, Evaluation and Deployment. These do not occur with unidirectional
flow [43, 47, 50].
Figure 2.3: Phases of CRISP-DM 41.
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1. Business Understanding: This phase is essentially characterized by the understanding of
the objectives, from a business perspective, that are intended to be achieved through the use
of DM. At the same time, a plan is implemented to achieve these objectives.
2. Data Understanding: It is necessary to know and identify the essential data of the problem,
so that it can be clearly described. The data comes from a variety of sources and may be
available in a variety of formats. In this step, one can use grouping techniques.
3. Data Preparation: In this step the data is prepared so that the DM methods can be used. To
do this, the data cleaning process is used: filter, combine and fill empty values, so that the
data will have the characteristics and quality required for the application of the DM methods
to be performed and the results satisfactory.
4. Modeling: This phase involves the selection and subsequent application of DM algorithms.
This choice is based on the objectives previously defined. The construction of a model is
aimed at stability, that is, it is intended to make forecasts that are not only useful in decision
making, but also remain true when applied to data not yet seen.
5. Evaluation: This step is extremely important, since it precedes the implementation of the
model. Thus, it is necessary to evaluate in detail the model and to review what was done for
its construction, in order to ensure that it responds adequately to the established objectives.
To do this, we use specialists who will perform tests and validations, in order to guarantee
the reliability and purpose of the model.
6. Deployment: Finally, it is necessary to organize and present knowledge in a way that the
client can use. Deployment involves steps such as planning, monitoring and maintaining
the plan, producing the final report, and reviewing the project. These, most of the time, are
performed by the client and not by the analyst.
Data Mining Tasks
DM has the ability to perform tasks that can be categorized into two types: descriptive data mining
(unsupervised learning) and predictive data mining (supervised learning). The first is characterized
by presenting the data set and by highlighting the relevant general properties of the data, in order
to discover patterns interpretable by the users. On the other hand, the second one is essential in the
construction of models, being useful in the prediction of the behavior of new cases [40, 50, 52].
Commonly, a DM system can perform, among others, the following tasks: Classification,
Regression, Association Rules Discovery and Clustering. The Classification is known as one
of the most used predictive tasks, and can be supervised. Defined by Elmasri [42] as "the process
of learning a function that maps (classifies) a given object of interest into one of the possible
classes". The goal is therefore to assign an object, characterized by a set of attributes, to one of
a finite set of labels (the class value). It involves a set of steps: data preprocessing, modeling,
selection of learning/selection of resources and validation/evaluation. The model obtained by the
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classification can be represented in the form of classification rules (if-then), Support Vector
Machines (SVM), Decision Tree, Random Forest, Naive Bayes, among others [43, 53, 54].
Rule-based classification is often retrieved from a decision tree. Nowadays, Sequential Cov-
erage algorithms such as AQ, CN2 and RIPPER, algorithms are used as a strategy for obtaining
directly the rules [43, 53, 54].
Support Vector Machine - SVM is a supervised machine learning algorithm that is used both
in classification and regression 42, 43. This is characterized by being a binary non-probabilistic
classifier. This is observed, since after taking an input dataset, it predicts, for each input taken,
which of the two possible classes includes the input, separating a set of objects with different
classes 44, [55].
Each training example is represented as a point in space. These are mapped so that a straight
line divides them into categories. This line should be as far away as possible from the classes
that are closest to the line. So, depending on which side of the line a new example is mapped,
SVM predicts which of the classes this example belongs to. In some situations, the data are not
linearly separated, and it is necessary for the SVM algorithm to resort to the kernel function. This
is responsible for transforming the space of the training examples, so that they are presented in an
n-dimensional space and that a hyperplane separates their classes [55].
Decision Trees are a very efficient and relevant algorithm type for predictive modeling ma-
chine learning 45, 46, [56]. The presentation of the data is done in the form of an inverted tree, that
is to say, the root of the tree is in the top and this one is dividing in branches from the direction
of upwards downwards. The input attributes are represented by the inner nodes of the tree. Each
branch represents a possible result for this test. The classes that the algorithm is trying to predict
are represented by the lower nodes, called sheet nodes [55].
The use of this algorithm is advantageous, since it is not only easy to interpret, it also does
not require much preparation of the data and it can deal with missing values. In contrast, this
algorithm can originate super-complex trees, causing overfitting [55].
In each recursion of any decision tree algorithm the following steps are used:
- Selection of an attribute A that will be divided;
- Subdivision of attribute A in disjoint subsets;
- A tree is returned with attribute A as root and with a set of branches on the lower level. Each
branch will have a descending sub tree;
421.4. Support Vector Machines. Available in http://scikit-learn.org/stable/modules/svm.html, accessed last time in
27-05-2017
43Understanding Support Vector Machine algorithm from examples (along with code), by SUNIL RAY , 2015. Avail-
able in https://www.analyticsvidhya.com/blog/2015/10/understaing-support-vector-machine-example-code/, accessed
last time in 27-05-2017
44Support Vector Machines (SVM) Introductory Overview. Available in http://www.statsoft.com/Textbook/Support-
Vector-Machines, accessed last time in 27-05-2017
451.10. Decision Trees. Available in http://scikit-learn.org/stable/modules/tree.html, accessed last time in 27-05-
2017
46Classification And Regression Trees for Machine Learning, by Jason Brownlee, 2016. Available in
http://machinelearningmastery.com/classification-and-regression-trees-for-machine-learning/, accessed last time in 27-
05-2017
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- Generally, the tree stops branching when all examples have the same label value. In parallel,
there are other conditions that cause the recursion to end: There are less than a number of instances
or examples in the current sub tree; This can be adjusted through the parameter minimum size for
split; No attribute achieves a given minimum gain relative to the existing tree before that division;
This can be set via the minimal gain parameter; And finally, the maximum depth is reached. This
can be adjusted through the maximal depth parameter.
There are several algorithms designed for the construction of decision trees: ID3, C4.5, CART
and CHAID. These are essentially distinguished by the criterion that decides which next node to
be explored and the type of test performed at each node inside the tree. In the set of experiences
carried out in this dissertation (described in 3.1.2), the CART decision tree algorithm was used. In
this type of algorithm, the choice of node A is made according to a selection criterion: metric Gini
Index or Gini Impurity. Thus, the node that presents a smaller impurity measure is selected [55].
Such impurity can be calculated as follows:
GiniIndex( f ) =
J
∑
i=1
f i(1− f i) (2.1)
Being that:
- J is the number of classes;
- fi corresponds to the fraction of items labeled with class i.
Random Forest is considered a machine learning algorithm that generates a set of decision
trees using sampling with replacement in the original dataset. The number of decision trees gen-
erated is specified by the programmer. This algorithm gives rise to a model that results from the
voting among all the generated random trees. This means that, for example, a certain attribute "a"
belongs to class "1", if this attribute was predicted by most trees generated as belonging to class
"1" 47, [55].
It is important to note that the decision trees are generated in a very similar way to the algo-
rithm described previously. Instead of node selection being made among all available nodes to be
branched, Random Forest selects the node between a random set of nodes 48, [55].
Finally, Naive Bayes is a simple supervised learning algorithm based on the Bayes’ theorem.
This is characterized by adopting the so-called conditional independence of class, that is, considers
that the presence or absence of an attribute is independent of the presence or absence of another
attribute. Naive Bayes assumes that each molecular descriptor independently contributes to the
probability of the drug causing the adverse effects under study. This becomes advantageous since
the algorithm does not require a large amount of training data to estimate the parameters required
for classification 49.
47Random Forests Algorithm, by Michael Walker, 2013. Available in
http://www.datasciencecentral.com/profiles/blogs/random-forests-algorithm, accessed last time in 27-05-2017
483.2.4.3.1. sklearn.ensemble.RandomForestClassifier. Available in http://scikit-
learn.org/stable/modules/generated/sklearn.ensemble.RandomForestClassifier.html, accessed last time in 27-05-2017
49How To Implement Naive Bayes From Scratch in Python, by Jason Brownlee, 2014. Available in
http://machinelearningmastery.com/naive-bayes-classifier-scratch-python/, accessed last time in 27-05-2017
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Thus, we have given a role = label ’C’ attribute of classes c1, c2, ..., cn is an attribute vector
’a’ corresponding to all other attributes, the conditional probability of a ci class may be expressed
as 50:
P(C = ci|a) = P(C = ci)∗P(a|C = ci)
P(a)
(2.2)
Naive Bayes kernel is a type of Naive Bayes. This one, unlike Naive Bayes, allows the use
of continuous numerical attributes, being used in non-parametric estimation techniques. This
operator is then based on kernel density estimation [55].
Thus, the conditional probability P(a|C=ci) will be calculated as the estimate of the kernel
density for class ci, such that:
P(a|C = ci) = fi(a) (2.3)
with
fi(a) =
1
Nh
N
∑
n=1
Ki
(a−an)
h
(2.4)
Being that:
-an represents a training point;
-Ki(a,an) represents the kernel function;
-h represents a smoothing parameter;
-N represents the total number of classes;
’h’ is usually called bandwidth (bandwidth) and is a parameter chosen by the programmer
[57].
A regression task predicts numbers and not labels (as in classification). Regression algorithms
include statistical Linear and Logistic Regression, Artificial Neural Networks (ANN) and others
[43, 45, 49].
In the task of Association Rules Discovery, association rules are created, based on how often
the items occur together. That is, the intention is to identify frequent correlations among items,
structuring regularities and affinities between them, in order to help the understanding of patterns
[42, 45, 58].
A clustering task is quite different from the previous ones. Clustering aims the identification
of groups with in the data. Contrary to the classification, it is not necessary to categorize the
records in advance (unsupervised learning). Clustering is a descriptive task and can be used in
image processing, data analysis, pattern recognition and many other domains. Some of the most
used algorithms in clustering are K-Means and K-Medoids. The K-Means algorithm accepts an
integer k and partitions the data in k clusters. Then, the objective is to calculate the similarity
between the objects analyzed and the center of each cluster, with the object being inserted in the
50Naive Bayesian, by Dr. Saed Sayad. Available in http://www.saedsayad.com/naive_bayesian.htm, accessed last
time in 27-05-2017
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cluster with the greatest similarity, that is, with a smaller distance. Finally, whenever a new ele-
ment is inserted, the center of the cluster is recalculated. In turn, the K-Medoids is a variation of
the former. This algorithm is concerned with the concept of the most central object of the clus-
ter. The most well-known implementations are PAM (Partitioning Around Medoids) and CLARA
(Clustering LARge Applications) algorithms. An alternative method to clustering is the Density-
Based Methods. Given a set of points in some space, it groups together points with many nearby
neighbors, marking as outliers points that lie alone in low-density regions (whose nearest neigh-
bors are too far away). This type of method has the capacity to obtain more satisfactory results, in
situations where the distribution of data values is more dense. Density-Based Spatial Clustering of
Applications with Noise (DBSCAN) is defined as being a fairly common algorithm of this type 51,
[41, 49, 52].
Data Mining Tools
In order to allow professionals from other areas to benefit from DM and in order to facilitate its
use, tools have been developed. Throughout this report, we will cover four popular tools that have
been widely used [43].
The Waikato Environment for Knowledge Analysis (WEKA) tool was implemented in 1997
in New Zealand. It is an open source software written in Java, which allows it to run on different
platforms. It implements a series of machine learning algorithms which gives it the ability to per-
form several DM tasks, such as: classification, regression, clustering, association rules discovery
and visualization. Its great advantage derives from the fact that it allows comparing techniques,
verifying which one presents a lower error rate 52, 53, 54, [43, 48].
RapidMiner, developed in 2001, is an open source tool written in Java and a no-coding re-
quired software. It uses both descriptive and predictive techniques, which allows to make cost-
effective decisions. RapidMiner has algorithms to construct models for predictive analysis and
also enables the graphical visualization of the results. Its use is advantageous as it ensures that
complex analyzes and resulting forecasts can be integrated directly into the customer’s infrastruc-
ture 52, [43, 48].
In turn, KNIME was considered the tool with the best performance and graphical interface.
This one is also open source and is written in Java and was developed with the purpose of finding
patterns. To do this, it applies algorithms to the data. It is used primarily in data preprocessing.
51A Tutorial on Clustering Algorithms. Available in https://home.deib.polimi.it/matteucc/Clustering/tutorial_html/km
eans.html, accessed last time in 30-12-2016
5212 Data Mining Tools and Techniques. Available in https://www.invensis.net/blog/data-processing/12-data-
mining-tools-techniques, accessed last time in 30-12-2016
53"Mineração de dados com WEKA, Parte 1: Introdução e regressão." Available in
https://www.ibm.com/developerworks/br/opensource/library/os-weka1/, accessed last time in 30-12-2016
54"Weka 3: Data Mining Software in Java." Available in http://www.cs.waikato.ac.nz/ml/weka/, accessed last time
in 30-12-2016
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Its graphical interface allows users to not only create data streams, perform the analysis steps, but
also analyze the results 52, 55, [43, 48].
Finally, R is a scripting language, written in C and FORTRAN and is available on platforms
such as Windows or Linux. Lately, interest in this tool has been increasing. This is verified since
R is a fundamental tool in the development of decision support and data analysis systems such
as the execution of complex tasks involving programming. It can be used in linear and nonlinear
modeling, classification, clustering, and graphical and data analysis. As a disadvantage, it has an
unfriendly interface 52, 56, [43, 48].
Metrics used to evaluate models
In order to test how a DM classifier model behaves on unseen data and to assess its quality, it
is extremely important to use good evaluation practices. Different metrics have been proposed
to evaluate classification models. It is important to note that different metrics aim to evaluate
different characteristics of the classifier. Data classification problems are usually divided into
binary, multiclass, and multi-labelled classification. In general, the metric measurement tool aims
at evaluating the classifiers’ performance and effectiveness. Accuracy, Precision, Recall, AUC
and F-Measure represent some metrics for classification tasks 57,58, 59.
Accuracy (acc) and error rate (err=1-accuracy) are known to belong to the group of metrics
most commonly used to evaluate the generalization of classifiers, either in binary classification
problems or in multiclass classification problems. These have the potential to differentiate each
single solution and choose for the optimal designated solution, produced by a particular classifi-
cation algorithm, from a large solutions space. For this, acc metric is based on the proportion of
correct predictions about the total instances, that is, its function is to measure how many times the
classifier makes the correct prediction 57, [3, 59, 60]. The accuracy is defined as below:
t p+ tn
t p+ f p+ tn+ f n
(2.5)
where, tp - true positive for C; fp - false positive for C; fn – false negative for C; tn - true negative
for C.
On the other hand, the error rate reflects the proportion of errors committed in the whole set
of instances and uses the percentage of incorrect forecasts to evaluate the solution produced. The
error rate is defined as below:
55Examining the KNIME open source data analytics platform. Available in
http://searchbusinessanalytics.techtarget.com/feature/Examining-the-KNIME-open-source-data-analytics-platform,
accessed last time in 30-12-2016
56What is R? Available in https://www.r-project.org/about.html, accessed last time in 30-12-2016
57 Turi Machine Learning Platform User Guide. Available in https://turi.com/learn/userguide/evaluation/classification.html,
accessed last time in 04-01-2017
58Testing and Validation (Data Mining). Available in https://msdn.microsoft.com/en-us/library/ms174493.aspx, ac-
cessed last time in 04-01-2017
59Model Evaluation. Available in http://www.saedsayad.com/model_evaluation.htm, accessed last time in 04-01-
2017
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f p+ f n
t p+ f p+ tn+ f n
(2.6)
where, tp - true positive for C; fp - false positive for C; fn – false negative for C; tn - true negative
for C.
From this it is verified that these metrics complement each other. The use of these metrics
has many advantages, of which the fact that they are easily calculable and understandable by the
users and of being applicable to problems called multiclass and multi-label. Regarding the error
rate metric, the metric accuracy presents some disadvantages: its simplicity can lead to suboptimal
solutions. Accuracy does not differentiate classes (positive or negative) 52, [3, 59, 60].
Metrics F-Measure (FM) and Area Under the ROC Curve (AUC) are also known to show
good performance as a discriminator in binary classification problems. AUC is used primarily for
imbalanced dataset. Despite its effectiveness, AUC presents a high computational costs, especially
when it is used to discriminate solutions in multiclass classification problems, which is a limitation
in its use. The performance of a classifier is portrayed by the value of the AUC metric. For a perfect
classifier, AUC is equal to 1 [3, 59, 61].
The F-Measure is defined as below:
2∗ p∗ r
p+ r
(2.7)
where, p - precision; r - recall.
The AUC value can be calculated as below:
Sp−np(nn+1)/2
np ∗nn (2.8)
where, Sp is the sum of the all positive examples ranked, while np and nn denote the number of
positive and negative examples respectively.
Contrary to these, the Precision and Recall metrics do not have the ability to opt for the
optimal solution, since they only have one evaluation task (positive or negative class) and they
prove to be less reliable than the AUC metric. Generally, these metrics are used together. Precision
allows you to identify, among the actual predicted items by the classifier, which are actually true 60,
[3, 59, 60]. The precision is defined as below:
t p
t p+ f p
(2.9)
where, tp - true positive for C; fp - false positive for C.
Recall can also be called sensitivity and designates the proportion of actual positive cases that
are correctly identified 60, [3, 59, 60]. The recall is defined as below:
60 Classification Accuracy is Not Enough: More Performance Measures You Can Use, by Jason Brown-
lee, 2014. Available in http://machinelearningmastery.com/classification-accuracy-is-not-enough-more-performance-
measures-you-can-use/, accessed last time in 04-01-2017
24 Survey on Adverse Drug Reactions and Data Mining
t p
t p+ tn
(2.10)
where, tp - true positive for C; tn - true negative for C.
The Table 2.1 below presents a summary of the relevant characteristics of the most used met-
rics for classification problems.
Table 2.1: Threshold Metrics for Classification Evaluations [3].
METRICS: EVALUATION FOCUS:
Accuracy (acc) • In general, the accuracy metric measures the ratio of correct
predictions over the total number of instances evaluated.
Error Rate (err) • Misclassification error measures the ratio of incorrect predic-
tions over the total number of instances evaluated.
Precision (p) • Precision is used to measure the positive patterns that are cor-
rectly predicted from the total predicted patterns in a positive
class.
Recall (r) • Recall is used to measure the fraction of positive patterns that
are correctly classified.
F-Measure (FM) • This metric represents the harmonic mean between recall and
precision values.
Evaluation methodologies
The evaluation of the model is a crucial step in the DM. This step allows the estimation of the
performance of the models, so that the models with the best characteristics and that best represent
the desired one are selected 50.
Cross Validation (CV) is one popular method of evaluation of DM models. It allows you
to test each sample of the data set and avoids overlapping test sets. K-fold Cross Validation is
the most common type of CV. This involves dividing the data set into k approximately equal size
folds. The model construction is done k times and at each time one of the folds is used as test
set while the others are used as training set. It is important to note that before performing cross
validation, the subsets are stratified. In DM, normally the number of folds is 3, 5 and 10. As a main
advantage, it presents the fact of displaying accurate performance estimation. However, it reveals
some disadvantages: overlapped training data; underestimated performance variance 50, 61, 62,
[62]. The Figure 2.4 shows an example of the 2-fold Cross-Validation technique.
61Model evaluation, model selection, and algorithm selection in machine learning, by Sebastian Raschka, 2016.
Available in https://sebastianraschka.com/blog/2016/model-evaluation-selection-part3.html, accessed last time in 04-
01-2017
62How to Evaluate Machine Learning Algorithms, by Jason Brownlee, 2013. Available in
http://machinelearningmastery.com/how-to-evaluate-machine-learning-algorithms/, accessed last time in 04-01-
2017
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Figure 2.4: Example 2-fold Cross-Validation.
As can be seen by the figure above, the data is divided into 2, so 2 models are built. For each
model, half of the examples are used for training (represented by brown color) and the other half
of the examples are used for testing (represented by orange color).
In small data sets, k is equal to the sample size, n, that is, equal to the number of instances in
the data. In this case CV takes the name of Leave-One-Out Cross Validation (LOOCV). This
procedure ensures better data utilization and does not involve random sub-sampling. At the same
time, its use is advantageous, insofar as LOOCV presents an unbiased performance estimate. On
the other hand, it is quite expensive computationally and does not allow stratification. For this
reason, most of the time, it is only used when the sample sizes are small 53, 63, 64, [62]. The
Figure 2.5 shows an example of the Leave-One-Out Cross Validation technique.
Figure 2.5: Example Leave-One-Out Cross Validation.
As can be seen by the figure above, this method uses only one of its examples for testing
(represented by orange color), and all other examples as training (represented by brown color) . In
this way, as many models are created as there are examples (data).
Another were known model estimation technique is the Hold-Out method. This is character-
ized by dividing the data set into two main subsets. These are called: training set and test set.
Training set is used for the construction of the predictive model, the training stage. Sometimes the
training set is split into a "large" training set and a small validation set. Validation set is usually
used to prune the model and/or to tune parameters of the algorithm. Finally, the test set allows
63Cross Validation, by Jeff Schneider, 1997. Available in https://www.cs.cmu.edu/ schneide/tut5/node42.html, ac-
cessed last time in 04-01-2017
64Evaluating what’s been learned. Available in http://www.cs.ccsu.edu/ markov/ccsu_courses/DataMining-9.html,
accessed last time in 04-01-2017
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estimating not only the error rate of the classifier, but also the future performance of a model. The
Hold-Out method is easy to compute the train and test set and it presents independent training and
testing. However, it presents as a strong limitation that its evaluation can be highly varied, that is,
the evaluation performed may differ, since it does not use all available data and depends on the
way the training/testing division is made. Contrary to this, where some samples may never be-
come part of the test set, k-fold CV ensures that all samples are used for validation, which makes
this technique better than hold-out. It is concluded, therefore, that hold-out limitations can be
overcome by k-fold CV 50,54, [62].
The Figure 2.6 shows an example of the Hold-Out Cross Validation technique.
Figure 2.6: Example Hold-Out Cross Validation.
As can be seen by the figure above, the data set is divided into two subsets: training and test.
Typically, the training set is larger than the test set. In this case, 70% is for the training data
(represented by brown color) and 30% is for the test data (represented by orange color).
Another existing procedure that tries to overcome the limitations of Hold-Out, in very small
data sets, is called Bootstrapping. Bootstrapping is a resampling method with replacement to
form the training set and is used with great potential, especially for small samples. It has the
ability to quantify the uncertainty associated with a given estimator. The best known bootstrap
estimator is designated 0.632 bootstrap 55, 65, [62].
Limitations of Data Mining
As already mentioned, DM is characterized by its enormous potential in the process of knowledge
extraction. In particular, in the area of health, the contribution of DM is indisputable, since its use
may allow the identification of new disease patterns, making it possible for professionals to make
rapid decisions. Despite all the benefits derived from its use, this method is not infallible and thus
also presents some limitations that must be taken into account [43, 49, 50].
DM creates relationships and discovers patterns, yet does not necessarily explain them. Wang
et al. [43, 49, 50] divides these limitations into four categories: statistical, data accuracy and
standardization, technical and organizational.
It is essential to adapt the tasks and algorithms to be used for the intended purposes. In order
for the results to be well interpreted, it is necessary that the relations established between the
attributes be well defined. The number of variables used should be large. The success of using this
65Cross Validated. Available in http://stats.stackexchange.com/questions/103459/how-do-i-know-which-method-of-
cross-validation-is-best, accessed last time in 04-01-2017
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method depends greatly on the collected data, since the quality of the results obtained in the DM
will depend directly on the quality of data collection and organization. At the same time, a high
knowledge of the users is necessary [40, 43, 50].
Recommender Systems
The amount of digital information available on the Internet is enormous. This information over-
load is a major problem for users, since it makes it more difficult for them to access the items
that interest them. In an attempt to minimize this setback, were created the Recommender Sys-
tems (RSs) in mid-1990s. This strategy has the ability to predict what users prefer based on their
profile, their previous searches, and searches performed by users with similar interests. RSs have
as their main objective to filter information and provide researchers with only relevant and highly
correlated information. Thus, this method should provide adequate recommendations and sug-
gestions, helping and directing users to the items that, from the outset, better serve their needs
[1, 63, 64].
Currently, RSs play a key role on websites such as Amazon (https://www.amazon.com/), be-
cause these systems can also be useful and effective in increasing sales, since in suggesting prod-
ucts, they awaken the need and desire of the person to acquire them. These are also applied to
recommendations for movies, music, travel services, among others. The development of a RS
should take into account its purpose. Thus, in order to select the ideal algorithm and to promote an
effective man-computer interaction, it is necessary to consider the specific requirements, specifi-
cations and limitations. Most of these use various algorithms of machine learning and data mining
[1, 65].
RSs are a multidisciplinary field and can take two main groups:
-Item Recommendation: can further be divided into content-based recommendation.
-Item Rating Prediction: can further be divided into recommendation with collaborative filter-
ing.
The must relevant approaches will be presented. Is necessary understanding the features of
different recommendation techniques. Figure 2.7 shows the anatomy of different recommendation
filtering techniques.
Collaborative filtering (CF) is an approach that designates a recommendation algorithm
known to base its predictions on previous behaviors and opinions of other users with similar char-
acteristics and interests, in order to simulate user preference. Thus, the recommendations made to
the active user are based on items that other users with similar choices performed in the past. For
such, the CF builds a database of user preferences, then compares users with identical tastes, then
calculates the similarities between them and generates the recommendations. This technique is
considered the most popular and most implemented and subdivided into two categories: memory-
based and model-based. The first is obtained through user-based techniques and items. The second
is characterized by the construction of a model through previous classifications and its purpose is
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Figure 2.7: Recommendation techniques [1].
to solve the dispersion problems associated with RSs. For this, it uses association techniques,
Clustering, Bayesian networks and decision trees. Association rules mining algorithms present
the compressed data in order to improve both storage efficiency and performance. Clustering is
used, for example, in image processing, statistical data analysis or pattern recognition, and aims to
divide a set of data into a set of sub-clusters, thus reducing the set of candidates in collaboration-
based algorithms. Consequently, the recommendations are made based on the average of the
participation clusters. In the clustering method, K-means and Self-Organizing Map (SOM) are
known to be the most used. On the other hand, when user preferences change slowly over time
and, therefore, time is taken to construct the model, Bayesian classifiers are used. Finally, to clas-
sify examples that had not yet been seen and to handle items with missing characteristics, we used
the construction of a tree graph, called a decision tree. This method is more understandable than
techniques such as SVM and Neural Networks. Despite the advantages implicit in the use of CF,
such as: ability to recommend items in areas where there is not much content and produce, in most
cases, acceptable results; CF presents some limitations such as the fact that it requires not only a
large number of user feedbacks but also that users have purchased the same product in order to
create standards for recommendations 66, [1, 63, 65].
The algorithms exploited in this dissertation were those of predictive rating with collaborative
filtering. The extension used in this dissertation - Recommender extension - provides 10 options
of training algorithms for forecasting, being that, in this project, 3 were addressed: Matrix Fac-
torization, Slope One and User k-NN.
The matrix factorization has proved to be a promising methodology for collaborative filtering
recommenders, since it allows modeling various real-life situations. Recommendation systems
depend on different types of input data. These are generally presented in the form of a matrix
66Introduction to approaches and algorithms, 2013. Available in https://www.ibm.com/developerworks/library/os-
recommender1/, accessed last time in 22-12-2016
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with a dimension representing the users and another representing the items. It allows essentially
characterizing both items and users by factor (k) vectors inferred from item classification patterns.
This approach leads to a recommendation when there is high correspondence between item and
user factors 67.
The matrix R is considered to result from a set (in this project) of Drugs - D and a set of
ADR’s - A, where D is the users and A are the items. Thus, the matrix R of size |D|*|A| has all the
rating’s representative of the Drugs-ADR ratios. This recommendation algorithm intends to find
the matrices P (|D|*k) and Q (|A|*k) such that its product approaches the matrix R:
R≈ P∗QT (2.11)
The forecast of a rating (mi − a j) is obtained by calculating the scalar product of the two
vectors corresponding to the drug d_i and the adverse effect a_j:
ru,i = dTi a j =
k
∑
k=1
dika jk (2.12)
To obtain the P and Q matrices, the system minimizes the regularized quadratic error for each
Drugs-ADR pair between the predicted values and the set of known ratings:
e2i j = (ri j−
k
∑
k=1
pikq jk)2
β
2
k
∑
k=1
(||P||2 + ||Q||2) (2.13)
Note that the B parameter used in the formula is to prevent the model from overfitting. To do
so, this parameter attempts to control the magnitudes of the vectors so that P and Q are a good
approximation of R without containing large numbers 68.
Proposed in 2005 by Daniel Lemire and Anna Maclachlan, Slope-One represents an item-
based collaborative filtering algorithm for easy and efficient implementation. This algorithm aims
to solve the problem of data dispersion, generating recommendations, that is, it is applied when it
is necessary to fill the vacancies of the item-user matrix. Based on linear regression, it calculates
the mean difference between the scores of the two items [66, 67, 68].
Given a training set X, and any two items j and i with ratings uj and ui, respectively, the mean
deviation between item i and item j is taken as:
dev( j, i) = ∑
u∈S j ,i(X)
u j−ui
card(S j ,i(X))
(2.14)
To do that, this algorithm only considers the users who have classified the target items and also
considers the other items that have been evaluated by those same users. Note that card represents
the cardinality (number of elements in the set) [69, 70].
67MATRIX FACTORIZATION TECHNIQUES FOR RECOMMENDER SYSTEMS, by Yehuda Koren, Robert Bell
and Chris Volinsky, 2009. Available in http://www.usabart.nl/PTQR/sameer1.pdf, accessed last time in 27-05-2017
68Matrix Factorization Techniques For Recommender Systems, by Markus Freitag, Jan-Felix Schwarz, 2011.
Available in https://hpi.de/fileadmin/user_upload/fachgebiete/naumann/lehre/SS2011/Collaborative_Filtering/pres1-
matrixfactorization.pdf, accessed last time in 27-05-2017
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After calculating the average deviations, the forecast is calculated:
P(u) j =
1
card(R j)
∑
i∈R j
(dev j ,i+ui) (2.15)
where, (R j = i|i ∈ S(u), i 6= j,card(S j ,i(X))> 0) is the set of all relevant items.
User k-NN (k-Nearest Neighbor) designates a collaborative type of user-based filtering that
determines the grouping of these based on their similarities. Thus, it is verified that this algorithm
foresees a given rating of user "a" to item "i", calculating the degree of similarity that exists
between that user "a" and other users, that is, the "nearest neighbors" of user "a". Such a degree
can be obtained through the similarity of Cosine:
∑ni=1AiBi√
∑ni=1A2i
√
∑ni=1B2i
(2.16)
or Pearson’s Correlation:
∑ni=1(Ai− A¯)(Bi− B¯)√
∑ni=1 (Ai− A¯)2
√
∑ni=1(Bi− B¯)2
(2.17)
Being that:
-(AiBi) correspond to the ratings of user’s item ’a’ and ’b’, respectively;
-n is the total number of items sorted by users ’a’ and ’b’;
-(A¯B¯)corresponds to the average of all user ratings ’a’ and ’b’, respectively.
When user "a" is compared with other users, only the k-NN, that is, the closest/closest neigh-
bors are saved. This avoids overfitting the model. After this comparison, the user’s rating "a" to
item “i” results from multiplying the average of the ratings of the neighboring k’s most similar to
the user ’a’ by the measure of similarity between the user ’a’ and the neighbor in question 69, [71].
Another widely used approach today is called Content-Based Filtering (CBF). This is char-
acterized by, based on the profile, on the characteristics and behavior of the user, build a recom-
mendation for that user. That is, this technique depends on the metadata of the items and enhances
the recommendation of items similar to those that the user liked previously. Unlike CF, CBF
ignores the choices of other users. Like the above mentioned technique, there are some disadvan-
tages which arise in requiring a descriptive and organized knowledge of the user’s choices and
preferences before a recommendation is made for this. At the same time, its effectiveness is com-
promised, as it depends on the availability of user data. Finally, CBF faces the fact that it only
suggests items similar to those already chosen by the user, which can be a problem, since the user
may no longer be interested in this type of products. However, on the other hand, this type of
filtering can, within a short time, adjust its recommendations to new user preferences, which is
one of its main advantages 58, [1].
In order to overcome the limitations of the previously mentioned techniques and to increase the
effectiveness and precision of RSs, the hybrid approach emerged, resulting from the combination
69K-NN (RapidMiner Studio Core), by RapidMiner, 2017. Available in
https://docs.rapidminer.com/studio/operators/modeling/predictive/lazy/k_nn.html, accessed last time in 27-05-2017
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of CF and CBF. This technique tries to use the advantages of CF to appease the disadvantages of
CBF and the opposite also happens. It follows that the use of combined algorithms, in most cases,
is more favorable and has better results than the use of individual algorithms 58, [1, 63, 65].
2.3 Ontologies and standards
It is common practice by both research organizations and companies to store large amounts of
information. That enormous amount of information and data has to be selected, organized and
treated. For each domain there are terms, definitions, relations, etc that can be used and interpreted
differently by the community. Thus, there is the need to develop ontologies in order to standardize
concepts, create norms and cross data, allowing the establishment of coherence and consensus
among this community. These ontologies play a crucial role, since they can be considered as
a formal representation of knowledge, whose main objective is to facilitate communication and
sharing between community and to improve an existing information organization 70.
In 1993, Tom Gruber [72] defined ontology as "a specification of a conceptualization, or a
description of concepts and relationships that exist between these concepts". Years later, in 1997,
Borst [72], on the other hand, classified ontology as "a formal specification of a shared concep-
tualization". Thus, in general, it is considered that the ontologies, created by specialists, specify
concepts, define terms and relations that are essential to model a domain. The concept of ontol-
ogy is ambiguous and depends on the context in which it is being used. Usually these are a set
of classes organized in a hierarchy. In the context of computing, more specifically, in database
systems, the ontological term is used for integrated heterogeneous data banks, enabling interop-
erability between different systems and specifying interfaces for independent knowledge-based
services 70, [73, 74, 75].
The use of ontologies promotes a clearer organization of information. At the same time, they
allow for better communication and information sharing among people, so as to promote coercion,
clarity and understanding about a domain, eliminating inconsistencies in the representation of
knowledge. On the other hand, despite its remarkable relevance, there are some drawbacks that
can be considered. It is necessary that the ontologies be updated and evolve and not go through
a process of stagnation. For this, it is fundamental to have found tools for the construction of the
same and that are described methodologies for its development. Finally, there is a large number of
languages to encode, which makes it impossible to exchange data between systems and a transfer
of knowledge they do not share the same languages [73, 74, 75].
In this section, three types of ontologies are addressed: Ontologies for Medical application,
Ontologies for Drug Reactions and Ontologies for Chemoinformatics.
70Ontologies and Semantic Web. Available in http://www.obitko.com/tutorials/ontologies-semantic-web/what-is-
ontology.html, accessed last time in 13-12-2016
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2.3.1 Encoding Ontologies
Ontologies are formalized using ontological languages, that is, formal languages. Ontology lan-
guages enable the encoding of terms from specific domains and rules of reasoning that support the
processing of knowledge. Ontological languages are declarative by nature. Most of the time, they
are generalizations of framework languages and are based on first-order logic or on description
logic 71, [76].
The Web Ontology Language (OWL) is an indispensable technology for the future implemen-
tation of the Semantic Web. OWL has been defined as a language that allows not only defining,
but also instantiating, ontologies on the Web. It enables the processing of information content
and interpretation by machines. Because it is based on eXtensible Markup Language (XML), it
facilitates the exchange of information between different types of computers, using programming
languages 71, [76].
There are several traditional languages of syntax ontology, among which we can highlight:
Common Logic, F-Logic, Developing Ontology-Grounded Methods and Applications (DOGMA),
KM programming language, among others 71.
2.3.2 Domain Ontologies
Ontologies for Medical application
In order to facilitate and standardize communication between a medical community and improve
understanding about human diseases, the Disease Ontology (DO) has been developed. This intends
semantically integrate medical vocabularies, thus allowing coherence in the description of terms
related to human diseases. These terms are related to well-established terminologies, such as
SNOMED 72, which contain not only human diseases, but also concepts related to them. This open
source ontology allows the crossing of data between symptoms, signs, and genetics or infectious
diseases 73.
Ontologies for Drug Reactions
Thus, in the attempt to standardize and integrate data in the domain of adverse reactions caused
by medical interventions, whose objective is to alleviate pains or prevent diseases, the Ontology
of Adverse Effects (OAE) has been created. This biomedical ontology, based on the community,
is also aimed at computer-aided reasoning 74, 75, [2, 77]. In OAE, an "adverse event is defined as
a pathological bodily process that is induced by medical intervention" 72, [2, 77].
71Web Ontology Language, 2016. Available in https://en.wikipedia.org/wiki/Web_Ontology_Language, accessed
last time in 15-01-2017
72SNOMED International SNOMED CT Browser. Available in http://browser.ihtsdotools.org/?, accessed last time
in 15-01-2017
73Disease Ontology, 2016. Available in http://disease-ontology.org/, accessed last time in 09-12-2016
74Ontology of Adverse Events. Available in https://bioportal.bioontology.org/ontologies/OAE, accessed last time in
10-12-2016
75AE. Available in http://www.oae-ontology.org/, accessed last time in 10-12-2016
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To better understand the mechanisms of induced adverse reactions and to facilitate the orga-
nization of the information and the existing content, one appeals the aid of diverse resources of
vocabulary, such as the MedDRA, the World Health Organization-Adverse Reaction Terminology
(WHO-ART) and the Common Terminology Criteria for Adverse Events (CTCAE). MedDRA is
known a vocabulary of codification of adverse events preferred by the FDA and used in such a
way for the Vaccine Adverse Events Reporting System (VAERS), as for FDA Adverse Event Re-
porting System (FAERS). In turn, the WHO keeps dictionary WHO-ART with the goal that this
serves of base for the rational codification of terms of adverse reaction. Finally, the USA National
Cancer Institute (NCI) developed vocabulary CTCAE so that he is used in the evaluation of ADRs
associated with cancer therapy drugs. These vocabularies intend, from individual data, symptoms
or illnesses, to distinguish the common characteristics and aspects not perceivable 72, 73, [2, 77].
The OAE presents a hierarchic relation of terms. There is a database called ADReCS which
provides the standardization and hierarchical classification of four levels of ADR terms. As shown
in Figure 2.8, the adverse effect of different types are divided in subclasses and classified in accor-
dance with the type of medical intervention [2, 77].
Figure 2.8: Key terms in OAE [2].
Currently, this ontologie presents 484 representational units, written down by means of 369
terms with specific AEO identifiers and 115 terms with specific OAE identifiers [2, 77].
Ontologies for Chemoinformatics
As is known, the amount information available in chemistry domain has been increasing rapidly.
This presupposes a more efficient and coherent organization of data. In order to filter, retrieve and
elucidate information, it is essential, through computational processing, to hierarchically organize
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knowledge. Thus, the ontologies have been used in order to promote a better management of data
in large volume and to allow a hierarchical classification concise [78, 79, 80].
The Chemical Entities of Biological Interest (ChEBI) ontology constitutes a database, which
is freely available (https://www.ebi.ac.uk/chebi/), and can be used for purposes such as text min-
ing. It is responsible for grouping chemical entities, such as atoms, molecules, and creating sim-
ilarity patterns. Based on structural chemical characteristics, biological functions and system
interactions, ChEBI provides a nomenclature and a hierarchical classification of the molecules
[78, 79, 80].
The hierarchical classification of molecules has many advantages. Allowing not only narrow-
ing in the area of interest within a large domain, but allowing a compact representation of the
generalized knowledge at the highest level to which it applies, therefore, a search and access to
people become easier. In addition, the hierarchical organization also plays a key role with respect
to useful predictions and the prediction of properties of new entities [78, 79, 80].
It is important to emphasize the importance of the ontologies for the molecules, since an
interpretation of biological mechanisms can allow the detection of bioactivity patterns associated
with the chemical structure of the molecules [78, 79, 80].
2.4 Related work
After conducting an in-depth research on the subjects and subjects in question and being fully
aware of them, it was extremely necessary and useful to carry out a search for the work that has
already been done in this area. The main purpose of this research is based on the fact that it
is important and necessary to know what has already been done, what methods/tools/strategies
have been used, what conclusions have been obtained, the progress achieved, the problems faced,
what can be improved and, essentially, which has not yet been done and which could bring great
progress in this area. This will ensure potential and effectiveness of the technology for predicting
ADRs during drug development.
It has been verified that some researches have already been done that use Data Mining algo-
rithms and tools for this purpose. As an example, a study by Diogo Pinto et al. [81]. In this
investigation, the main objective was focused on the use of algorithms and, in their subsequent
evaluation, for recommendation systems. For this, data from the ADReCS database were used.
The results were satisfactory in that Diogo Pinto et al. was able to show that the technology used
allowed the forecast of ADRs, mainly in the pre-commercialization phase.
All the investigations carried out, even those that did not observe such satisfactory results, are
extremely useful and relevant to future conclusions. It is important to test, use different method-
ologies, experiment with tools, make observations, continue studies and conduct research, so that
techniques can be applied successfully and above all, can bring benefits and safety to the health of
the world population.
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2.5 Chapter Summary
This chapter it was presented the relevant basic concepts on the domain of adverse drug reactions
and Data Mining.
The relevant Web repositories to be used in the study were also identified. The survey on the
Data Mining algorithms have also helped to make a decision on which ones to use. As is usual
on scientific studies, methodologies and metrics were investigated and established to evaluate the
experiments this project.
It is important to remember that ontologies are important and useful in that they intend to stan-
dardize concepts and create norms, in order to establish a consensus on the available information.
This allows a better organization of the same, which leads to a clearer and more precise commu-
nication/sharing of knowledge. There are several types of ontologies, and in this work only those
that may have interest in the future work were addressed.
The ontology survey made in this chapter was useful to assess whether the use of additional
information in the field of chemistry can improve the performance of data mining algorithms.
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Chapter 3
Experimental evaluation
The dissertation work is composed by a set of Data Mining experiments to answer the two re-
search questions stated in section 1.2. The case studies of this project used data sets from the
ADReCS and DrugBank databases. The data and information available in these databases were
pre-processed to make them adequate for the analysis tools. Subsequently, with the aid of enrich-
ment tools, namely PaDEL and Open Babel, the processed data were enriched, in order to perform
ADR prediction on new drugs. Lastly, the data were transformed into a suitable format for the DM
methods and tools and finally, models were constructed (see Figure 3.1).
Figure 3.1: Web repositories, workflow of the analysis tasks and tools involved in the research
work.
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In the experimental part of our work, we started by replicating Diogo’s work [81] previously
discussed in 2.4. We have used recommendation systems as Diogo and then, evolved to classifi-
cation tasks. In this set of experiments, the ADReCS database (described in 2.1) was used. The
table 3.1 shows the methodology for this. Recommendation system was used as predictive meth-
ods only, whereas the classification can provide potential explanations for the ADR apart from the
predictive facility.
Table 3.1: ADR prediction with Recommender Systems using ADReCS.
For the classification tasks, a previous data enrichment stage was performed. The enrichment
was done with addition of molecular descriptors. It was evaluate if the amount of drug infor-
mation improves both the predict made but also the potential explanations given (implicit in the
models). That is, it was observed to what extent the use of more information can be more useful
and advantageous. The table 3.2 below shows the methodology for this.
Table 3.2: ADR prediction experiments with classification algorithms using ADReCS.
The Data Mining tool chosen to carry out the process was RapidMiner, since it has an easy
to use interface and enables the definition of the Data Mining’s steps workflow. The version of
RapidMiner used was educational one, since it allows free and unrestricted access of the number
of lines to students and teachers.
After the analysis of ADReCS data, we have investigated the problem of drug to drug inter-
action. For that purpose, we have used the DrugBank database. DrugBank (described in 2.1) is
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a freely available database. It is considered a unique biology and chemistry resource that con-
tains detailed data not only of drugs, but also of the amino acid sequence, structure and route of
administration 1.
Briefly, this project focused on two case studies. In the first case study, two experiments were
made with the ADReCs database data. The first experience focused on the prediction of existing
drug-adverse effects pairs. Thus, we only used information from the databases and used algo-
rithms of recommendation systems that was responsible for the prediction. The recommendation
algorithms used were Matrix Factorization (MF), Slope-One and User k-NN. Models performance
were assessed using obtaining the metrics: Accuracy, Precision, Recall and F-Measure. The sec-
ond experiment was mainly intended to find not only drug-adverse effects relationships, but also
biochemical justifications for their existence. To this end, classification methods were used as de-
scribed in 2.2. The classification algorithms used were Decision Tree with CART, Random Forest
with CART, Naive Bayes and Support Vector Machine (LibSVM). In addition to the available in-
formation in the databases, we have added data related to the molecular descriptors of each drug.
The performance of the model was measured by obtaining the metrics: Accuracy, Precision, Re-
call and F-Measure. The last case study involved only the pre-processing of the data taken from
DrugBank.
Therefore, this chapter essentially addresses the relevant information regarding the content of
the data used and describes in detail all the steps involved in the realization of the experiments.
3.1 Case Study 1
3.1.1 Experiment 1
Data pre-processing
This case study used data sets from the ADReCS 2 (described in 2.1). This database is only avail-
able in XML format, and was converted to the CSV format, format accepted by the RapidMiner
tool.
As is usual, the original data was preprocessed in order to select only the most relevant one
for the study. The data reduction process performed in the data preprocessing phase is very useful.
This allows to reduce the training time of each algorithm and improve the model quality, since
infrequent attributes could lead the model to make noise-based decisions, thus causing overfitting
of the system.
In this experiment, we have used the leaf nodes of the ADR hierarchy. The original data
contained about 1353 drugs and 6722 ADR’s. In order to reduce not only the drugs but also the
less frequent adverse effects, the data was filtered. Thus, all drugs with less than 100 associated
adverse effects were eliminated. In parallel, all adverse effects that occurred less than 3 drugs
were also eliminated.
1DrugBank. Available in https://www.drugbank.ca/about, accessed last time in 09-06-2017
2http://bioinf.xmu.edu.cn/ADReCS/
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At the end of the data pre-processing, we obtained a file with 615 drugs and 3058 adverse
effects. The CSV format of the data can be seen as a matrix where each line has information
concerning a single drug and each column has information concerning a single ADR. Apart from
first line and first columns that have names, each cell I, j stores a 0 if there are no ADR caused by
line I drug and a 1 if drug in line I causes ADR at column.
Recommendation Process
In order for the RapidMiner recommendation process operators to apply the recommendation sys-
tems discussed in 2.2, it was necessary to use a name recommender extension (http://www.e-
lico.eu/ Recommender-extension.html) provided by RapidMiner. The algorithms exploited were
those of predictive rating with collaborative filtering.
The general recommendation process achieved is presented in the Figure 3.2.
Figure 3.2: Recommendation Process.
Note that the "Read CSV" operator was first used in order to read the CSV file obtained in
the pre-processing phase described previously in 3.1.1. Figure 3.3 shows a sample of data with 3
attributes: Drug, ADR, Rating.
Figure 3.3: Sample of data.
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Later, in order to relate each of the three existing attributes - Drug, ADR, Rating - with Role
predefined by the extension used - "user identification", "item identification" and "label" - the
operator "Set Role" was used. As can be seen in the following figure (Figure 3.4), the drugs were
considered the users and the adverse effects were considered items/content.
Figure 3.4: Parameters used in the "Set Role" operator.
"Split Data" operator was next used. This operator partitions the input data set into subsets
according to the specified relative sizes. The "Recommendation Algorithm" operator is the next
in the analysis workflow. In order to use recommender systems, we had to install an extension
to RapidMiner. The RapidMiner extension used provides 10 options of training algorithms for
forecasting. In this project, we have used 3: Matrix Factorization, Slope One and User k-NN
(described in 2.2). Next in the workflow is the "Apply Model" operator. It is responsible for
receiving the training model, that is, it receives the model constructed using the training set. The
test file, which contains the Drug-ADR pairs whose rating will be predicted is also provided. In the
output, we have a file with one more attribute, namely "prediction" attribute. The last sub process,
called "Performance", compotes the metrics Accuracy, Recall, Precision and F-Measure. These
are presented as a percentage. The higher the percentage, the better the model performance. This
sub process comprises 6 operators (Figure 3.5). The first one, called the "Set Role", was applied
in a way to convert the Role of the regular prediction attribute to prediction.
Figure 3.5: "Performance" sub process.
Then, the operator "Numerical to Binomial" was used to transform the prediction attribute to
the binomial type. These two conditions were necessary in order to be able to subsequently apply
the operator "Performance Binomial Classification". This resulted, on the part of the prediction
attribute, from a transformation of examples <0.5 in false and examples >= 0.5 in true. In order
to compare the "prediction" attribute with the "rating" attribute, the examples of the prediction
attribute were converted from true to 1 and from false to 0. This was accomplished with the two
operator "Replace". The "Set Role" operator (Figure 3.6) was applied again in a way to convert
the Role of the prediction attribute to prediction.
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Figure 3.6: Parameters used in the "Set Role (3)" operator.
In the Figure 3.7, it can be seen a sample of the output file.
Figure 3.7: Sample of the output file.
Finally, the operator "Performance Binomial Classification" was applied. This allowed obtain
the accuracy, recall, precision and F-Measure metrics (detailed in 2.2).
To assess the robustness of the methods, we have produced two data sets by introducing two
different noise-levels in the original data. The data sets used was prepared with 5% and 10% noise
and the procedure previously described was performed 2 times for each noise level. The effect
of noise on the value of the accuracy metric and, consequently, in the model performance was
recorded.
3.1.2 Experiment 2
Data pre-processing
In this experience, we have used 26 groups of ADRs ids. ADRs ids are organized in an hierarchy
and we have merged the levels of the hierarchy into the top level ids of the hierarchy. That is, the
previous ADR has become an ADR of group 3, identified by the first 2 digits of the identifier. The
Figure 3.8 present the 26 nodes, corresponding to the 26 groups of adverse effects explored in the
present experiment.
Taking into account that the results matrix, contrary to the results matrix of previous experi-
ment, is quite dense, it was necessary to eliminate the drugs whose adverse effects cover many of
the groups of adverse effects presented previously.
The database was enriched with a set of attributes called molecular descriptors, which qualifies
each drug relative to its typology, molecular constitution, among other properties. To do this, all
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Figure 3.8: Groups of adverse effects at level 1 of the hierarchy.
the SMILES formulas to represent molecules was used (example: Aspirin - CC (= O) Oc1ccccc1C
(= O) O), through a Java program that accesses the ChemSpider webserver 3.
Subsequently, we used the web server PaDEL Descriptors to obtain the molecular descriptors.
It is important to note that in order not to reduce the number of drugs to use, we chose to ignore
the 3D descriptors, since this platform only provides 3D descriptors for only 333 drugs in the
ADReCS database.
Some attributes representing molecular descriptors have been removed because they produce
a large number of missing values.
Next, we created the attribute that the algorithms will try to predict, that is, the "label" attribute.
This was taken from the ADReCS database, using the adverse effects hierarchy. The "groupADR"
attribute of role = label has taken values of true or false. When " groupADR" = true, it is assumed
that the investigational medicinal product has adverse effects relating to the group of adverse
effects in question. When “groupADR" = false, it is stated that the medicinal product in question
is not responsible for causing any of the adverse effects relating to the group of adverse effects in
question. This can be observed in a small sample below (Figure 3.9), which is related to group 1
of adverse effects - blood and lymphatic system disorders.
3Available in http: /www.chemspider.com/, accessed last time in 27-05-2017
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Figure 3.9: Sample of the file corresponding to the groupADR=1.
After the data treatment, we obtained a data set consisting of "Name", "GroupADR" and 1524
molecular descriptors. This set contains 340 drugs. During the execution of the process, only 10
molecular descriptors were selected.
Classification Process
It is important to recall that this experiment is mainly intended to find not only drug-adverse effects
relationships, but also biochemical justifications for their existence. For that, four classification
algorithms were used: Decision Tree with CART, Support Vector Machine (LibSVM), Random
Forest with CART and, finally, Naive Bayes (detailed in 2.2). Taking into account the nature of
the molecular descriptors used in this set of experiences, it was necessary to resort to the "Naive
Bayes (kernel)" operator. Each of these classification algorithms was executed 26 times, which
corresponds to the number of adverse effects groups in the study. Each trial attempts to predict
whether or not the medicinal products have adverse effects from the group of adverse effects under
study.
The flow chart representative of the classification process is presented in the Figure 3.10.
Figure 3.10: Classification Process.
As can be seen, this process was started with the "Read CSV" operator. This operator is
responsible for reading the file. The input file used was that obtained in data pre processing
(described in 3.1.2). This includes a "Name" attribute, a "groupADR" attribute, and a set of
attributes representative of the molecular descriptors of each drug.
After reading the file, it was necessary to change the role of the attribute "groupADR" from
"regular" to "label", so that the use of any classification algorithm was possible. To do this, the
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"Set Role" operator was applied. It is important to emphasize that it is the classification algorithm
that makes the forecast according to this attribute.
We have then applied the operator "Normalize" to all attributes in the database. This was
fundamental to transform all the attributes, in order for all to have the same range of values. That
is, it was intended to prevent attributes with large values would have a greater influence in the
forecast.
Next, the most important attributes for the study were identified. Least important attributes
were discarded. This feature selection was achieved with the help of the "Weight by Correlation"
and "Select by Weight" operators. The first one, calculates the importance (weight) of a given
attribute. This weight corresponds to the correlation between each input attribute and the label. We
should mention that the greater the weight of a given attribute, the greater its relevance. Correlation
measures the degree of association between an attribute and the label and is comprised between -1
and +1 and is obtained by Pearson’s correlation. It is considered that when an attribute "a" gets a
positive correlation, it is directly proportional to the label. On the other hand, when the attribute
"a" gets a negative correlation, it is inversely proportional to the label. It should be noted that the
"Weight by Correlation" operator cannot be applied to polynomial attributes, since in these, the
weights are considered random [55].
The "k" attributes of greater weight were selected by the "Select by Weight" operator. In our
experiments, the ’k’ parameter was set to 10. According to the previous operator, the best 10
attributes, in descending order of relevance, were:
1. CrippenLogP- Atom-based calculation of LogP using Crippen’s approach;
2. VR2_Dt- Normalized Randic-like eigenvector-based index from detour matrix;
3. MDEN-33- Molecular distance edge between all tertiary nitrogens;
4. LipoaffinityIndex- Is an "efficiency indicator";
5. nHBint9- Count of E-State descriptors of strength for potential Hydrogen Bonds of path length 9;
6. MATS4v- Moran autocorrelation - lag 4/weighted by van der Waals volumes;
7. XLogP- Prediction of logP based on the atom-type method called XLogP;
8. AATSC4v- Average centered Broto-Moreau autocorrelation - lag 4/weighted by van der Waals vol-
umes;
9. nF6HeteroRing- Number of 6-membered fused rings containing heteroatoms (N, O, P, S, or halo-
gens);
10. GATS4v- Geary autocorrelation - lag 4/weighted by van der Waals volumes 4;
4http://www.scbdd.com/padel_desc/descriptors/
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The selection of attributes by this operator is important because it helps to perceive which
descriptors most significantly influence the activity of the molecules. These 10 attributes were
selected as the best and used for the 4 classification algorithms used in the experiment.
Finally, the algorithms were tested using the k-fold Cross-Validation methodology with k=10.
This operator was automatically subdivided into the training model, which contains one of the four
classification operators chosen and the test model, which includes the "Apply Model" operator and
the "Performance" sub process. RapidMiner workflow of this part is shown in Figure 3.11.
Figure 3.11: Cross-Validation process.
The "Apply Model" operator is responsible for receiving the model constructed using the
training data, that is, it receives the model trained using the train data, on its first port. The
test file, which contains the Drug-groupADR pairs whose rating will be predicted, is received on
the second port. The last sub process, called "Performance", had as its main objective to obtain
the metrics Accuracy, Recall, Precision and F-Measure (detailed in 2.2). These are presented as a
percentage. The higher the percentage, the higher the performance of the model.
3.2 Case Study 2
3.2.1 Experiment 1
Data pre-processing
The present case study consists of performing the pre-processing of the data from the DrugBank
data sets 5 (approached in 2.1).
This database provides a list of molecules with a lot of characteristic features. These features
include the molecule id in different "standards", its SMILES representations, the family it belongs,
a list of molecules with whom it is known to interact among other valuable chemical information.
Then, with the help of PaDEL tool, the SMILES representation was enriched with a set of
attributes called molecular descriptors. Only 1D and 2D descriptors were generated.
Subsequently, it was necessary to convert the format of the molecules interacting with the
above molecules into the SMILES format (example: 2-Methoxyestradiol - COC1=C(O)C=C2CCC3
C4CC[C@H](O)[C@@]4(C)CCC3C2=C1) To this, we resorted to the DrugBank repository. Then,
5https://www.drugbank.ca/about
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with the help of the PaDEL Descriptors, the SMILES was enriched with a set of attributes called
molecular descriptors. Only 1D and 2D descriptors were generated.
Finally, was composed of a set of data.
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Chapter 4
Results
In this chapter, we present and discuss the results obtained with the realization of the experiments
described in Chapter 3. Some relevant conclusions are also presented.
4.1 Case Study 1
Experiment 1
This experiment involves the use of the RapidMiner recommender extension, which provides 10
options of training algorithms for forecasting. Only 3 - Matrix Factorization, User k-NN and Slope
One - were considered in this project. The objective was to measure the performance of the model
by obtaining the metrics: accuracy, precision, recall and F-Measure.
The Accuracy metric represents the percentage of correct predictions made by the model. At
the same time, the percentage achieved by the Precision metric is related to the actual existence of
the adverse effects predicted by the system, in the real world. That is, the main error lies in the
actual 0’s being predicted as 1’s. In turn, the Recall metric is responsible for measuring the actual
adverse effects that the system can predict as actually adverse effects. Finally, the relationship
obtained between the Precision and Recall metrics gives the metric F-measure. Recall that the
higher F-Measure, the better the model’s performance.
The following table (Table 4.1) shows the results for noise-free data:
Table 4.1: Results obtained for the metrics under study.
Accuracy (%) Precision (%) Recall (%) F-Measure (%)
Matrix Factorization 45.15 (+/-1.18) 33.22 (+/-0.20) 54.05 (+/-0.57) 41.54 (+/-0.75)
User k-NN 35.54 (+/-1.35) 26.76 (+/-0.59) 50.14 (+/-4.18) 34.75 (+/-1.46)
Slope One 21.57 (+/-0.12) 20.64 (+/-0.16) 44.74 (+/-0.47) 27.89 (+/-0.23)
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Observing Table 4.1, it is possible to see that the algorithm that obtained the best performance
was Matrix Factorization. Note that the higher the percentage of the metrics, the better the perfor-
mance of the model. The worst results were obtained with the Slope One algorithm.
Analyzing the results obtained, it can be stated that for the Matrix Factorization algorithm, the
precision metric suggests that 33.22% of the adverse effects foreseen by the system are actually
adverse effects in the real world. It is also observed that the recall metric indicates that the system
can find 54.05% of the actual adverse effects.
Such results may be justified, since the Matrix Factorization algorithm is the only one that
predicts, considering adverse effects and drugs. On the other hand, the classification of a drug
made by the User k-NN algorithm is based on similarities with another group of drugs. In turn,
the prediction of classifications of an adverse effect obtained with the Slope One algorithm is
supported by the classifications of another adverse effect.
In the User k-NN operator, as expected, the value of k (number of users - Drug - with which
the user under study will be compared) is has a strong influence on the algorithm’s performance.
We have observed that the performance is higher for low the values of k. We have used k=1.
The following results presented in two tables are one for each of the noise level introduced in
the data set. For each noise level two data sets were generated so the algorithm was run 2 times
for each noise value, and the results shown in the table correspond to the average and standard
deviation of the results obtained in each one.
Table 4.2 shows the mean of the values obtained for the data with 5% of noise.
Table 4.2: Average results obtained for the metrics under study with 5% of noise.
Accuracy (%) Precision (%) Recall (%) F-Measure (%)
Matrix Factorization 39.43 (+/-0.98) 30.32 (+/-0.19) 51.15 (+/-0.49) 38.74 (+/-0.67)
User k-NN 31.63 (+/-1.23) 24.24 (+/-0.55) 47.65 (+/-3.76) 32.53 (+/-1.23)
Slope One 19.53 (+/-0.17) 17.63 (+/-0.14) 42.53 (+/-0.41) 23.63 (+/-0.21)
Observing Table 4.2, it is possible to see that the algorithm that obtained the best performance
was Matrix Factorization. The worst results were obtained with the Slope One algorithm.
Table 4.3 shows the mean of the values obtained for the data with 10% of noise.
Table 4.3: Average results obtained for the metrics under study with 10% of noise.
Accuracy (%) Precision (%) Recall (%) F-Measure (%)
Matrix Factorization 34.75 (+/-0.87) 27.42 (+/-0.16) 47.85 (+/-0.45) 34.63 (+/-0.54)
User k-NN 28.53 (+/-1.12) 21.42 (+/-0.51) 44.63 (+/-3.01) 29.75 (+/-1.12)
Slope One 16.35 (+/-0.10) 14.65 (+/-0.11) 39.64 (+/-0.36) 19.75 (+/-0.18)
Observing Table 4.3, it is possible to see that the algorithm that obtained the best performance
was Matrix Factorization. The worst results were obtained with the Slope One algorithm.
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Comparing the results presented in the 3 previous tables, it is possible to state that the percent-
age of the values of the metrics decreases with the increase of the noise in the data, which leads to
the conclusion that the noise interferes and decreases the performance of the model.
Experiment 2
Contrary to experiment 1 (described in 3.1.1), which aims to provide for an individual ADR, this
focuses on predicting which groups of adverse effects are felt when taking a medicinal product.
In this experience, we have used classification algorithms that best allow us to know the most
important attributes in the classification. This can be very useful and relevant insofar as such
knowledge can assist the experts in understanding the cause of the adverse effect. Thus, for the
accomplishment of this project, the classification algorithms chosen were: Decision tree with
CART, Random Forest with CART, Naive Bayes and Support Vector Machines (LibSVM).
Then, 4 tables will be presented, one for each classification algorithm used. It should be noted
that the experiment was performed for 26 adverse effects groups using a 10- fold Cross Validation.
In order to optimize the results obtained, the attribute pre-selection was done with the weight by
correlation.
For a better understanding of the table, it is important to note that the first column shows
the ADR group to be tested. The Accuracy, Precision class=true and Recall of class=true are
represented respectively in the second, third and fourth columns. Precision class=false and Recall
class=false are shown in the fifth and sixth columns. Finally, in the last column, are presented the
values obtained for the F-Measure metric.
In the table 4.4, it is possible to observe the results obtained using the Decision Tree algorithm
with CART.
The results table show that group 8 was the one that obtained the higher Accuracy. On the
other hand, the lowest Accuracy metric was obtained in group 4.
Looking of the Decision Tree generated for the best group of adverse effects under study
(group 8), can see that the best molecular descriptor (root of the tree) is the CrippenLogP 1. This
descriptor means the atom-based calculation of LogP using Crippen’s approach.
In the table 4.5, it is possible to observe the results obtained using the Random Forest.
Looking at the results we can see that group 8 was the one that obtained the metric Accuracy
higher. On the other hand, the lowest Accuracy metric was obtained in group 9. Comparing with
the previous results (shown in Table 4.4), the present Accuracy results slightly better (14/26 of the
groups tested). In Figure 4.1, this improvement is perceptible.
Figure 4.1 also allows us to verify that the groups that suffered a greater difference in the Ac-
curacy values were the groups that obtained the worse values, when using the algorithm Decision
tree, that is, the groups 4, 5 and 21.
In Table 4.6, the Naive Bayes results are shown.
1http://www.scbdd.com/padel_desc/descriptors/
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Figure 4.1: Results of the Accuracy metric obtained using the Decision Tree with CART and the
Random Forest algorithms.
As with the algorithms used previously, the group that obtained a higher Accuracy was group
8. On the other hand, the lowest Accuracy was obtained in group 4. Compared with the results
obtained with the Random Forest algorithm, the Naive Bayes algorithm obtained a lower Accuracy
in 22/26 of the groups of adverse effects under study.
In Table 4.7, it is possible to observe the results obtained using Support Vector Machine (SVM)
with kernel Radial Basis Function (RBF).
As with the algorithms used previously, the group that obtained a higher Accuracy metric was
group 8. On the other hand, the lowest accuracy metric was obtained in group 4.
Figure 4.2 shows a graph with the Accuracy results obtained when using the above mentioned
4 algorithms. This allows a clearer observation of the results. Thus, it is clearly noticeable that
the group that obtained the value of the highest Accuracy metric was group 8 and the best result
of this is obtained when using the Support Vector Machine algorithm - about 94.41%. In general,
the group that presented the worst results was group 4.
In the table 4.8, it is possible to observe the Accuracy average obtained for each algorithm
used.
SVM was the algorithm that obtained the best Accuracy (about 75.32%), for the 26 groups of
adverse effects under study. Then, with about 75.25%, the Random Forest algorithm appears.
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Figure 4.2: Results of the Accuracy metric obtained using the Decision Tree with CART, Random
Forest, Naive Bayes and Support Vector Machine algorithms.
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Table 4.4: Results obtained in the experiment 2 - Decision Trees with CART.
GroupADR Accuracy
(%)
Precision (T)
(%)
Recall (T)
(%)
Precision (F)
(%)
Recall (F)
(%)
F-Measure
(%)
G1 60.59 (+/-
1.95)
61.03 97.58 44.44 3.01 5.63
G2 78.53 (+/-
1.35)
78.53 100 0.00 0.00 -
G3 80.00 (+/-
2.56)
80.84 98.54 33.33 3.03 5.56
G4 53.24 (+/-
4.64)
47.22 21.94 54.85 79.46 61.56 (+/-
15.34)
G5 57.65 (+/-
4.40)
61.90 16.88 57.05 91.40 70.05 (+/-
4.19)
G6 63.82 (+/-
3.24)
63.43 98.59 72.73 6.25 11.51
G7 87.35 (+/-
2.65)
88.13 99.00 0.00 0.00 -
G8 94.12 (+/-
2.63)
95.20 98.75 42.86 15.79 23.08
G9 56.18 (+/-
5.49)
52.01 96.27 85.71 20.11 32.58
G10 80.88 (+/-
2.71)
82.37 97.48 36.36 6.45 10.96
G11 62.35 (+/-
1.76)
62.72 99.07 0.00 0.00 -
G12 60.00 (+/-
1.44)
60.18 99.51 0.00 0.00 -
G13 74.12 (+/-
3.43)
74.85 97.60 57.14 8.89 15.38
G14 77.94 (+/-
3.54)
78.44 97.67 70.00 16.87 27.18
G15 68.24 (+/-
3.54)
68.96 98.30 20.00 0.95 1.82
G16 71.18 (+/-
3.17)
100.00 6.67 70.57 100.00 82.75 (+/-
1.82)
G17 89.12 (+/-
2.96)
90.45 98.38 0.00 0.00 -
G18 90.00 (+/-
2.70)
90.48 99.35 50.00 5.88 10.53
G19 79.41 (+/-
1.86)
79.45 98.85 78.57 14.10 23.91
G20 65.59 (+/-
3.24)
66.04 96.36 57.89 9.17 15.83
G21 54.71 (+/-
6.47)
52.69 59.76 57.14 50.00 47.41 (+/-
17.68)
G22 75.59 (+/-
2.96)
76.60 97.67 45.45 6.10 10.75
G23 91.18 (+/-
2.94)
92.49 98.40 28.57 7.41 11.76
G24 89.12 (+/-
1.35)
89.05 100.00 100.00 5.13 9.76
G25 77.94 (+/-
3.01)
50.00 13.33 79.69 96.23 87.12 (+/-
2.20)
G26 82.94 (+/-
2.20)
54.55 10.17 83.89 98.22 90.49 (+/-
1.20)
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Table 4.5: Results obtained in the experiment 2 - Random Forest.
GroupADR Accuracy
(%)
Precision (T)
(%)
Recall (T)
(%)
Precision (F)
(%)
Recall (F)
(%)
F-Measure
(%)
G1 61.76 (+/-
2.28)
61.99 96.14 57.89 8.27 14.47
G2 78.53 (+/-
1.35)
78.53 100 0.00 0.00 -
G3 80.00 (+/-
2.56)
80.65 98.91 25.00 1.52 2.86
G4 57.06 (+/-
6.20)
58.49 20.00 56.79 88.11 68.99 (+/-
4.70)
G5 67.06 (+/-
7.18)
70.19 47.40 65.68 83.33 73.57 (+/-
5.06)
G6 65.00 (+/-
4.82)
64.86 95.75 66.67 14.06 23.23
G7 88.24 (+/-
2.65)
88.25 100.00 0.00 0.00 -
G8 93.82 (+/-
2.06)
94.38 99.38 0.00 0.00 -
G9 55.88 (+/-
7.78)
53.90 47.20 57.29 63.69 56.95 (+/-
16.28)
G10 81.47 (+/-
1.88)
81.71 99.64 0.00 0.00 -
G11 63.82 (+/-
2.65)
64.00 97.20 60.00 7.14 12.77
G12 59.71 (+/-
2.96)
60.24 97.56 37.50 2.22 4.20
G13 75.29 (+/-
2.70)
75.30 98.80 75.00 10.00 17.65
G14 77.94 (+/-
3.54)
78.26 98.05 72.22 15.66 25.74
G15 68.53 (+/-
2.30)
69.39 97.45 40.00 3.81 6.96
G16 71.18 (+/-
3.17)
100.00 6.67 70.57 100.00 82.75 (+/-
1.82)
G17 89.71 (+/-
2.37)
90.75 98.70 20.00 3.12 5.41
G18 90.00 (+/-
2.70)
90.48 99.35 50.00 5.88 10.53
G19 78.24 (+/-
3.28)
78.66 98.47 66.67 10.26 17.78
G20 65.59 (+/-
2.65)
65.65 98.18 63.64 5.83 10.69
G21 59.71 (+/-
6.45)
57.71 59.76 61.82 57.95 57.42 (+/-
14.90)
G22 75.29 (+/-
2.35)
76.20 98.06 37.50 3.66 6.67
G23 92.09 (+/-
1.35)
92.06 100.00 0.00 0.00 -
G24 88.82 (+/-
1.76)
89.02 99.67 66.67 5.13 9.52
G25 78.53 (+/-
2.65)
62.50 6.67 78.92 98.87 87.75 (+/-
1.66)
G26 83.24 (+/-
1.35)
66.67 6.78 83.53 99.29 90.73 (+/-
0.71)
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Table 4.6: Results obtained in the experiment 2 - Naive Bayes algorithm.
GroupADR Accuracy
(%)
Precision (T)
(%)
Recall (T)
(%)
Precision (F)
(%)
Recall (F)
(%)
F-Measure
(%)
G1 60.29 (+/-
9.87)
70.45 59.90 49.39 60.90 54.91 (+/-
8.69)
G2 60.29 (+/-
7.81)
89.76 55.81 32.18 76.71 45.51 (+/-
6.15)
G3 74.93 (+/-
3.52)
82.03 88.32 27.27 18.46 22.02
G4 58.82 (+/-
6.58)
54.39 60.00 63.31 57.84 60.16 (+/-
7.60)
G5 66.47 (+/-
7.18)
62.05 66.88 70.69 66.13 68.49 (+/-
9.62)
G6 64.71(+/-
7.67)
69.33 77.83 53.92 42.97 47.08 (+/-
13.59)
G7 82.56 (+/-
3.77)
89.25 91.33 16.13 13.16 14.49
G8 91.43 (+/-
2.76)
95.05 95.94 13.33 11.11 12.12
G9 60.88 (+/-
11.09)
57.53 66.46 64.94 55.87 59.48 (+/-
12.86)
G10 67.65 (+/-
8.11)
88.89 69.06 30.65 61.29 41.17 (+/-
9.71)
G11 60.59 (+/-
6.34)
74.39 57.01 60.00 7.14 54.77 (+/-
10.46)
G12 57.94 (+/-
7.90)
66.46 60.98 47.37 53.33 49.82 (+/-
10.06)
G13 69.12 (+/-
3.01)
76.17 84.40 38.10 26.67 30.41 (+/-
9.63)
G14 71.76 (+/-
7.91)
78.05 87.16 37.74 24.10 29.84 (+/-
10.16)
G15 65.59 (+/-
4.93)
73.98 77.45 43.63 39.05 41.10 (+/-
6.95)
G16 70.59 (+/-
3.48)
64.71 10.48 70.90 97.45 82.02 (+/-
2.53)
G17 88.53 (+/-
3.59)
91.90 95.78 31.58 18.75 23.53
G18 90.29 (+/-
2.65)
90.99 99.02 57.14 11.76 19.51
G19 69.05 (+/-
9.36)
83.98 74.05 37.04 51.95 43.34 (+/-
14.20)
G20 55.88 (+/-
7.44)
66.36 64.55 38.10 40.00 38.13 (+/-
13.25)
G21 66.47 (+/-
9.59)
63.74 70.73 69.62 62.50 65.37 (+/-
10.97)
G22 62.94 (+/-
6.73)
78.45 70.54 29.63 39.02 33.22 (+/-
10.03)
G23 82.65 (+/-
6.37)
93.79 86.90 18.88 33.33 23.38
G24 81.47 (+/-
6.84)
88.39 91.03 10.00 5.69 8.70
G25 72.06 (+/-
5.46)
40.00 53.33 85.42 77.36 81.12 (+/-
3.91)
G26 78.24 (+/-
7.35)
40.00 50.85 89.06 83.99 86.28 (+/-
5.02)
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Table 4.7: Results obtained in the experiment 2 - Support Vector Machine (SVM) algorithm.
GroupADR Accuracy
(%)
Precision (T)
(%)
Recall (T)
(%)
Precision (F)
(%)
Recall (F)
(%)
F-Measure
(%)
G1 60.29 (+/-
2.71)
60.71 98.55 25.00 0.75 1.46
G2 78.53 (+/-
1.35)
78.53 100.00 0.00 0.00 -
G3 80.59 (+/-
2.35)
80.77 99.64 50.00 1.52 2.94
G4 58.82 (+/-
8.63)
58.06 34.84 59.11 78.92 67.10 (+/-
8.78)
G5 66.76 (+/-
8.11)
74.12 40.91 64.31 88.17 74.42 (+/-
5.93)
G6 64.71 (+/-
4.16)
64.56 96.23 66.67 12.50 21.05
G7 88.24 (+/-
0.00)
88.24 100.00 0.00 0.00 -
G8 94.41 (+/-
0.88)
94.41 100.00 0.00 0.00 -
G9 62.94 (+/-
10.12)
59.67 67.08 66.67 59.22 61.96 (+/-
12.79)
G10 81.76 (+/-
1.188.11)
81.76 100.00 0.00 0.00 -
G11 62.94 (+/-
1.44)
62.94 100.00 0.00 0.00 -
G12 60.29 (+/-
1.47)
60.29 100.00 0.00 0.00 -
G13 73.53 (+/-
1.32)
73.67 99.60 50.00 1.11 2.17
G14 77.35 (+/-
3.73)
77.27 99.22 80.00 9.64 17.20
G15 69.12 (+/-
1.47)
69.12 100.00 0.00 0.00 -
G16 71.18 (+/-
3.17)
100.00 6.67 70.57 100.00 82.75 (+/-
1.82)
G17 90.59 (+/-
1.18)
90.59 100.00 0.00 0.00 0.00 (+/-0.00)
G18 90.88 (+/-
3.07)
91.29 99.35 71.43 14.71 24.39
G19 77.06 (+/-
1.18)
77.06 100.00 0.00 0.00 -
G20 64.71 (+/-
0.00)
64.71 100.00 0.00 0.00 -
G21 65.29 (+/-
7.65)
61.62 74.39 70.42 56.82 62.55 (+/-
9.13)
G22 75.29 (+/-
1.95)
75.74 99.22 0.00 0.00 -
G23 92.06 (+/-
1.35)
92.06 100.00 0.00 0.00 -
G24 88.53 (+/-
0.88)
88.53 100.00 0.00 0.00 -
G25 78.53 (+/-
2.30)
100.00 2.67 78.40 100.00 87.89 (+/-
1.33)
G26 83.82 (+/-
1.47)
100.00 6.78 83.63 100.00 91.09 (+/-
0.77)
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Table 4.8: Results of the Accuracy average (of the 26 adverse effects groups) for each of the
algorithms used.
Algorithm Accuracy average (%)
Decision Tree 73.92
Random Forest 75.25
Naive Bayes 70.43
Support Vector Machine 75.32
Chapter 5
Conclusions and Future Work
5.1 Satisfaction of Results
The occurrence of ADRs has been increasing notably in recent years and has reached the level of
concern. Many studies are being carried out to predict them. In general, it has been observed that
computing has proved essential in this area, since the development of predictive procedures could
help to avoid many unwanted serious effects.
The main goal of this dissertation was to assess how useful Data Mining methods and algo-
rithms could predict the adverse effect of drugs (detailed in 1.2). Thus, it was first necessary to
conduct in-depth not only of the basic concepts inherent to the adverse effects of drugs, but also a
set of DM methods and tools that would be very useful for predicting new adverse effects.
After the analysis of the state of the art was done, the experimental part of the project was
advanced. Such as the one outlined and in order to answer the two research questions mentioned
in 1.2, two case studies were addressed.
The first case study involves the realization of two experiments, whose data set was taken from
the ADReCS database.
In the first experiment, were used recommendation algorithms: Matrix Factorization, Slope
One and User k-NN. Considering the results obtained, it can be stated that the algorithm that ob-
tained a model with better performance was the Matrix Factorization, since this algorithm obtained
the value of the greater Accuracy metric (about 45.15%). Such results may be justified, since the
Matrix Factorization algorithm is the only one that predicts, considering adverse effects and drugs.
However, the results obtained were not promising.
In the second experiment, we have defined a classification tasks using only the top of the
ADRs identifiers hierarchy. Thus, 26 groups of adverse effects were explored. The classification
algorithms used were Decision tree with CART, Random Forest, Naive Bayes and Support Vector
Machine. Each of these classification algorithms was executed 26 times, which corresponds to
the number of adverse effects groups in study. It is important to remember that in this process a
feature selection was made, in which the 10 best attributes were selected. Considering the results
obtained, it can be stated that the algorithm that obtained a model with better performance was
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the Support Vector Machine, since this algorithm obtained on average the best value of Accuracy
(about 75.32%). The results obtained were satisfactory.
After analyzing the results obtained in the two experiments, it was observed that experiment 2
obtained better results. Thus, it is concluded that making individual predictions of adverse effects
is quite complex, and when reducing the detail of the information, that is, when one goes up the
level of hierarchy, the obtained results are better. It is important to note that this improvement of
results also occurs when done with the Feature Selection, since a pre-selection of the best attributes
occurs.
In response to the first research question posed in 1.2), the results obtained showed that the
Data Mining tool has potential and can be really useful for the prediction of ADR’s. However,
there are still many points that need to be worked on and improved.
The second research question can not be fully answered because only information on 1D and
2D molecular descriptors has been used. For such, it would be interesting to use ontologies and
3D molecular descriptors.
In the course of this work, it was verified that several previous studies claim that a very relevant
factor that can increase the number of ADRs episodes is the simultaneous consumption of more
than one drug. Thus, it is essential to study not only the occurrence of ADR episodes in isolation,
but also the possible drug interactions that may exist. These DDI may be at the origin of adverse
effects that would not be proven if the drugs were taken alone.
As the results obtained in case study 1, namely for experiment 2, were satisfactory, it was
found that it would be interesting to analyze DDI and to replicate the experience 2. Thus, to date,
was performed the preprocessing of the data (described in 3.2.1), whose data set was taken from
the DrugBank database for a possible DDI analysis.
5.2 Future Work
The simultaneous taking of several drugs is one of the most worrying and relevant issues in with
regard to the occurrence of adverse effects. Thus, in a future work, it would be interesting, using
the set of data obtained in 3.2.1 from the DrugBank database and replicate the process performed
in experiment 2 (detailed in 3.1.2) with classification algorithms.
It may be important to include in these set of experiences the ontologies described in 2.3, to
verify if additional information from the chemistry domain improves the performance of the Data
Mining algorithms and, consequently, improves the performance of the model.
Finally, another proposal would be to use other operators of pre-selection of attributes, in an
attempt to compare with the results already obtained, in order to analyze if it would influence the
performance of the model.
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